New formulation
A formulation combining DPP-IV inhibitors and metformin with specific excipients addresses the challenges of high drug loading and stability, resulting in tablets with improved compressibility and rapid disintegration.
Patent Information
- Application Number
- JP2024123496
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2005-09-29
- Filing Date
- 2024-07-30
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing formulations of DPP-IV inhibitors and metformin face challenges in achieving high drug loading with good stability, compressibility, and cohesive properties, making it difficult to produce tablets with acceptable size, hardness, and rapid disintegration.
A formulation comprising a DPP-IV inhibitor, such as vildagliptin, and metformin, utilizing specific excipients like microcrystalline cellulose and lactose, is developed through direct compression or wet granulation to create tablets with improved flow and compressibility, ensuring stability and rapid disintegration.
The formulation achieves tablets with high drug loading, good stability, and rapid disintegration, addressing the challenges of compressibility and tablet size, while maintaining the efficacy of both active ingredients.
Smart Images

Figure 2024167195000001 
Figure 2024167195000002 
Figure 2024167195000003
Abstract
Description
[Technical field]
[0001] The present invention relates to dipeptidyl peptidase IV (DPP-IV) inhibitors, preferably vildaglycerides. US201002326333A1 - Preparations containing metformin and metformin, tablets containing such preparations and methods for producing same - Google Patents It concerns the method. [Background technology]
[0002] Metformin is widely prescribed to lower blood glucose in patients with NIDDM. and is available in 500, 750, 850 and 1000 mg strengths. Because it is a short-acting drug, metformin can be administered twice or three times a day ( 500-850 mg tablets 2-3 times a day or 1000 mg twice a day with meals) is required. The biguanide hypoglycemic drug metformin disclosed in U.S. Pat. No. 3,174,901 is It is currently marketed in the United States in the form of its hydrochloride salt (Glucophage@, Bristol-Myers Squibb Company). The manufacture of metformin (dimethyldiguanide) and its hydrochloride salt is state of the art. And first by Emil A. Werner and James Bell, J. Chem. Soc. 121:1790-1794 (1922) Metformin may be administered in a form such as that commercially available under the trademark GLUCOPHAGE™. It can be administered at .
[0003] Meformin increases the sensitivity of the host's peripheral tissues to insulin. It also inhibits intestinal glucose absorption, suppresses hepatic gluconeogenesis and fatty acid oxidation. The appropriate dosage regimen for meformin is 500 mg two to three times daily. The unit dose comprises and can be five times a day, or even 850 mg one or two times a day. [Martindale, The Complete Drug Reference].
[0004] As used herein, the term "metformin" refers to metformin or the hydrochloride salt. , metformin (2:1) fumarate, and U.S. patent application Ser. No. 2003 / 0123634, filed Mar. 4, 1999. metformin (2:1) succinate, hydrobromide as disclosed in US Pat. No. 09 / 262526; p-Chlorophenoxyacetate or embonate, and U.S. Pat. No. 3,174,901 Other known metformin derivatives containing mono- and dibasic carboxylic acids, including those disclosed in US Pat. Metformin is a pharmacokinetic, pharmacokinetic, and pharmacokinetic (meth)amine salt. As used herein, metformin refers to metformin base acid, i.e., GLUCOPHAGE -D or GLUCOPHAGE XR (trademark of Bristol-Myers Squibb Company) It is preferable that the
[0005] In this context, the terms "DPP-IV inhibitors", "metformin", "glitazones" or "pyrimidines" are used interchangeably. Any specific glitazone, such as "oglitazone," "rosiglitazone," or any other suitable glitazone, may also be used. A pharma- ceutically acceptable salt, crystalline form, hydrate, solvate, diastereomer or enantiomer of It is intended to include sexual bodies.
[0006] Preferred DPP-IV inhibitor compounds of primary interest to the present invention are listed below: In this context, "DPP-IV inhibitors" also refers to the active metabolites and protoplasts of DPP-IV inhibitors. "Metabolites" are intended to include active metabolites thereof and prodrugs, such as prodrugs. is a derivative of DPP-IV inhibitors that is produced when DPP-IV inhibitors are metabolized. The "prodrug" is metabolized to or reacts with a DPP-IV inhibitor. These are compounds that are either metabolized by the same metabolite(s) or metabolized by the same metabolic entity.
[0007] DPP-IV inhibitors are known in the art. For example, DPP-IV inhibitors include No. WO98 / 19998, German Patent Publication No. 19616486A1, No. WO00 / 3 No. 4241, No. WO95 / 15309, No. WO01 / 72290, No. WO01 / 52 No. 825, No. WO9310127, No. WO9925719, No. WO9938501 , WO9946272, WO9967278 and WO9967279 In each case, both general and specific disclosures are made.
[0008] Preferred DPP-IV inhibitors are described in the following patent applications: WO020 No. 53548, in particular compounds 1001 to 1293 and examples 1 to 124, WO02 No. 067918, in particular compounds 1000 to 1278 and 2001 to 2159, WO No. 02066627, particularly the examples given, WO02 / 068420, particularly the examples All compounds specifically listed in I to LXIII and the corresponding analogs as described. Further preferred compounds are those listed in the table reporting IC50: 2(28), 2(88), 2(1 19), 2(136), WO02083128, especially Examples 1 to 13, US Pat. Patent application publication no. 2003 / 096846, in particular the compounds specifically described in WO200 4 / 037181, in particular the compounds of Examples 1 to 33 and claims 3 to 5; 68603, in particular the compounds of Examples 1 to 109; EP 1258480, in particular the compounds of Examples 1 to 109; The compounds of Examples 1 to 60, WO0181337, in particular Examples 1 to 118, WO0 No. 2083109, especially Examples 1A to 1D; No. WO030003250, especially Examples 1 to 166, most preferably 1 to 8, Compounds described in the examples, WO03 / 035057, in particular the compounds described in the examples; US Patent Application Publication No. 2003 / 216450, particularly Examples 1 to 450; WO 99 / 46272, in particular the compounds of claims 12, 14, 15 and 17, WO0197808 No. WO03002553, in particular the compounds of claims 2, and No. WO03002553, in particular the compounds of examples 1 to 33 , WO01 / 34594, in particular the compounds described in Examples 1 to 4, WO02051 836, especially examples 1 to 712; EP 1245568, especially examples 1 to 7 , EP 1258476, especially Examples 1 to 32; U.S. Patent Application Publication No. 2003 / 013366; No. 087950, particularly the examples described therein; WO02 / 076450, particularly example 1 128, WO03000180, particularly Examples 1 to 162, WO0300018 No. 1, in particular Examples 1 to 66; WO03004498, in particular Examples 1 to 33; No. 6,482,844, particularly those described herein. Examples of compounds that can be used include those listed in WO0155105, particularly in Examples 1 and 2, No. 0202560, particularly examples 1 to 166; No. WO03004496, particularly examples 1 to 103, WO03 / 024965, in particular Examples 1 to 54, WO03037 No. 27, particularly examples 1 to 209; WO0368757, particularly examples 1 to 88; WO03074500, in particular Examples 1 to 72, Examples 4.1 to 4.23, Example 5. 1 to 5.10, Examples 6.1 to 6.30, Examples 7.1 to 7.23, Examples 8.1 to 8 .10, Examples 9.1 to 9.30, WO02038541, in particular Examples 1 to 53, WO02062764, in particular the compounds of Examples 1 to 293, preferably Example 95 ( 2-{{3-(aminomethyl)-4-butoxy-2-neopentyl-1-oxo-1,2 hydrochloride dihydro-6-isoquinolinyl}oxy}acetamide),
[0009] WO02308090, particularly Examples 1-1 to 1-109 and Examples 2-1 to 2-9 , Example 3, Examples 4-1 to 4-19, Examples 5-1 to 5-39, Examples 6-1 to 6-4, Examples 7-1 to 7-10, Examples 8-1 to 8-8, Example 7-1 on page 90 7-7, pp. 91 to 95, Examples 8-1 to 8-59, Examples 9-1 to 9-33, Examples 10-1 to 10-20, U.S. Patent Application Publication No. 2003 / 225102, particularly the compound Compounds 1 to 115, compounds of Examples 1 to 121, preferably compounds a) to z), aa) or et al. a-z), ba) to bz), ca) to cz) and da) to dk), WO021427 No. 1, particularly Examples 1 to 320, and U.S. Patent Application Publication No. 2003 / 096857, The compounds specifically described in WO2004 / 052850, particularly in Examples 1 to 42, The product and the compound of claim 1, DE 102 56 264 A1, in particular from example 1 181 and the compound of claim 5, The compounds of the present invention are preferably those specifically described as listed in Table B, particularly those specifically described as listed in Table A. a compound according to any one of claims 6 to 49, preferably compounds I to XXXXVII, WO04 / 071454, in particular the compounds specifically described, for example compounds 1 to 53 or a compound of tables Ia to If, or a compound of claims 2 to 55, WO 02 / 06 No. 8420, in particular the specifically described compounds such as compounds I to LXIII, or Example I and Analogs 1 to 140, or Example 2 and Analogs 1 to 174, or Example 3 and Analogue 1, or Examples 4 to 5, or Example 6 and Analogues 1 to 5, Or Example 7 and Analogs 1-3, or Example 8 and Analog 1, or Example 9, or examples 10 and analogues 1 to 531, more preferably the compounds of claim 13. and specifically described in WO 03 / 000250, in particular compounds 1 to 166. The compounds according to the present invention, preferably the compounds according to Examples 1 to 9, and the compounds according to WO03 / 024942, in particular the compounds Specifically described compounds such as compounds 1 to 59, compounds (1 to 68) in Table 1, compounds of claim 6 , 7, 8, 9, WO03024965, in particular compounds 1 to 54 Compounds generally described in WO03002593, in particular in Table 1 or claims 2 to 15 The compounds specifically described in WO03037327, such as the compound in Example 1, Specifically described compounds, such as compounds of No. 209, WO 03 / 000250, The compounds specifically described in the above, such as compounds 1 to 166, are preferably those in the above examples 1 to 9. The compounds specifically described in WO03 / 024942, in particular compounds 1 to 59, the compounds of Table 1 (1 to 68), the compounds of claims 6, 7, 8 and 9, and WO0302 4965, in particular the specifically described compounds such as compounds 1 to 54, WO0300 No. 2593, particularly the specifically described compounds such as those in Table 1 or claims 2 to 15. The compounds specifically described in WO03037327, especially the compounds of Examples 1 to 209, Compounds to be used in the present invention, No. WO0238541, No. WO0230890, February 16, 2001 See U.S. Patent Application No. 09 / 788,173 (attorney file LA50), filed on 2006, specifically in the examples. Those described in WO99 / 38501, especially those described in the examples, WO99 / 46272, in particular those described in the examples, and DE 19616486 (A1), in particular the val- pyr, val-thiazolidide, isoleucyl-thiazolidide, isoleucyl-pyrrolidine and fumarate salts, such as those described in WO0238541, in particular the compounds of Examples 1 to 53 Specifically described compounds, WO03 / 002531, especially specifically described compounds Preferably, the compounds listed on pages 9 to 13, most preferably the compounds of Examples 1 to 46. The compound of the present invention and the further preferred compound of Example 9, U.S. Pat. No. 6,395,767, preferably is a compound of Examples 1 to 109, most preferably the compound of Example 60.
[0010] Further preferred DPP-IV inhibitors include 1[2-[(5-cyano(eyano)pyridine-2-yl] (2S)-1-[( 2S)-2-amino-3,3-dimethylbutanoyl]-2-pyrrolidinecarbonitrile Such U.S. Patent No. 6,124,305 and U.S. Patent No. 6,107,317, International Patent Application Publication No. Nos. WO9819998, WO9515309 and WO9818763 Disclosed examples are included.
[0011] WO9819998 describes N-(N'-substituted glycyl)-2-cyanopyrrolidines, in particular 1-[2-[5-cyanopyridin-2-yl]amino]-ethylamino]acetyl-2-cyano The present invention discloses an ano-(S)-pyrrolidine. The compounds are listed on pages 9 to 11 and are incorporated by reference into this application. Application WO0034241 and published U.S. Patent No. 6,110,949 each disclose N-substituted aryl groups. Damantyl-amino-acetyl-2-cyanopyrrolidine and N-(substituted glycyl)-4- Cyanopyrrolidines are disclosed. DPP-IV inhibitors of interest are specifically recited in claims 1 to 4. In particular, these applications disclose the compound 1-[[(3-hydroxy-1-adamantyl)
[0033] 2-cyano-(S)-pyrrolidine (also known as LAF237) (if any) will be stated.
[0012] WO9515309 describes the use of the amino acid 2-cyanopyrrolidine as an inhibitor of DPP-IV. amides, and WO9529691 discloses alpha-aminoalkylphosphonic acids. The present invention discloses peptidyl derivatives of diesters of the formula (I), particularly those containing proline or related structures. DPP-IV inhibitors of interest are in particular those cited in Tables 1 to 8. In / 72290, the DPP-IV inhibitors of interest are particularly described in Example 1 and claims 1, 4 and and 6. WO9310127 discloses a compound useful as a DPP-IV inhibitor. The present invention discloses a proline boronic ester having a DPP-IV inhibitor of interest, which is particularly Published patent application WO9925719 discloses a method for the preparation of streptomycin-derived erythrocytes. The present invention discloses a DPP-IV inhibitor, sulphostin, produced by culturing a microorganism containing sulphostin. WO9938501 discloses N-substituted 4- to 8-membered heterocyclic rings. DPP-IV inhibitors are especially those recited in claims 15 to 20.
[0013] WO9946272 discloses phosphoric acid compounds as inhibitors of DPP-IV. DPP-IV inhibitors of interest are in particular those recited in claims 1 to 23. Other preferred DPP-IV inhibitors are those listed in the patent application WO03 / 057200. The most preferred DPP-I compounds are those of formula I, II or III as disclosed on page 27 of the same reference. The V inhibitors are the compounds specifically described on pages 28 and 29. Published patent applications WO9967278 and WO9967279 disclose DPP-IV promoters. and ABC (where C is either stable or unstable) The present invention discloses an inhibitor in the form of
[0014] Preferably, the N-peptidyl-O-aroyl hydroxylamine has formula VII: [ka] (In the formula, j is 0, 1 or 2; R ε1 represents the side chain of a natural amino acid; and R ε2 represents lower alkoxy, lower alkyl, halogen or nitro) or a pharma- ceutically acceptable salt thereof.
[0015] In a highly preferred embodiment of the invention, N-peptidyl-O-aroyl hydroxylamines is represented by formula VIIa: [ka] or a pharma- ceutically acceptable salt thereof.
[0016] For example, N-peptidyl-O-aroylhydroxylamines of formula VII or VIIa and its preparation are described by HU Demuth et al. in J. Enzyme Inhibition 1988, Vol. 2, 129 -142, in particular pages 130-132.
[0017] Most preferably, the inhibitor has formula (I) in free form or in acid addition salt form. [ka] (In the formula, R is a substituted adamantyl; and (n is 0 to 3) N-(substituted glycyl)-2-cyanopyrrolidine.
[0018] The term "substituted adamantyl" includes alkyl, -OR 1 or -NR 2 R 3 Selected from adamantyl substituted by one or more, e.g., two, substituents, i.e. R refers to 1- or 2-adamantyl. 1 , R 2 and R 3 are hydrogen, a Rukill, (C 1 -C 8 alkanoyl), carbamyl or -CO-NR 4 R 5 and here R 4 and R 5 are independently alkyl, unsubstituted or substituted aryl, where R 4 Oh BiR 5 is further hydrogen or R 4 and R5 Let's go together 2 -C 7 Alkire Represents the
[0019] The term "aryl" preferably denotes phenyl. Substituted phenyl is preferably e.g. one or more selected from alkyl, alkoxy, halogen and trifluoromethyl; and phenyl substituted with more than one substituent, for example two substituents. The term "alkoxy" refers to alkyl-O-. The term "halogen" or "halo" refers to fluorine, chlorine, bromine and iodine. The term "alkylene" refers to alkylene having 2 to 7 carbon atoms, preferably 3 to 6 carbon atoms. Most preferably it refers to a linear bridge of 5 carbon atoms.
[0020] A preferred group of compounds of the invention are those in which the adamantyl substituent is a methyl group at or adjacent to the bridgehead. The compound of formula (I) is a glycyl-2-cyanopyrrolidine moiety linked to a styrene-based bridge. In compounds of formula (I) that are head-linked, the R' substituent of the adamantyl is 3-hydroxy. Preferably, the glycyl-2-cyanopyrrolidine moiety is attached to the methylene adjacent to the bridgehead. In the compounds of formula (I) where R' is an adamantyl group, the R' substituent is preferably 5-hydroxy. I wish.
[0021] The present invention particularly relates to compounds of formula (IA) or (I B): [ka] (In the formula, R' is hydroxy, C 1 -C 7 Alkoxy, C 1 -C 8 Alkanoyloxy or R5 R 4 N-CO-O-, where R 4 and R 5 is separately C 1 -C 7 Alkyl or non Substitution or C 1 -C 7 Alkyl, C 1 -C 7 Alkoxy, halogen and tri phenyl substituted by a substituent selected from fluoromethyl, 4 is further hydrogen; or R 4 and R 5 Let's go together 3 -C 6 Represents alkylene; do R'' represents hydrogen; or R' and R'' are C 1 -C 7 (representing alkyl) The present invention relates to a compound of the formula:
[0022] These DPP-IV inhibitor compounds of formula (I), (IA) or (IB) are known, and No. 6,166,063 issued Dec. 26, 2000 and WO 01 / 528 25. In particular, (S)-1-{2-[5-cyanopyridin-2-yl)amino] (S)-1-[(3-hydroxy- 1-Adamantyl)amino]acetyl-2-cyano-pyrrolidine (LAF237) is disclosed. They can exist in free form or in the form of acid addition salts. Of these, non-toxic and physiologically acceptable salts are preferred, but for example, the compounds of the present invention may be isolated or oxidized. Other salts are also useful in the preparation or purification of the compound. The preferred acid addition salts are the hydrochlorides, but the methyl salts are also useful. Salts of ethanesulfonic acid, sulfuric acid, phosphoric acid, citric acid, lactic acid and acetic acid may also be utilized. .
[0023] The preferred DPP-IV inhibitors are those listed in the article by Mona Patel and col. (Expert Opinion Investig. Drugs 12(4):623-33 (2003 Apr)), in particular those set out in paragraph 5 of P32 / 98, K -364, FE-999011, BDPX, NVP-DDP-728, etc. (Publications are available (hereby incorporated by reference) are specifically mentioned DPP-IV inhibitors. FE-999011 is identified as compound No. 18 on page 14 of patent application WO95 / 15309. It is described as follows.
[0024] Other preferred inhibitors are disclosed in U.S. Pat. No. 6,395,767 (compound of Example 60). The compound BMS-477118 is disclosed in Patent Application No. WO2004 / 052850, p. 2. (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyphenyl)-2-propanediol represented by formula M Xytricyclo[3.3.1.1 3,7 ]dec-1-yl)-1-oxoethyl]-2-azabicyclo[1.2.1] Chloro[3.1.0]hexane-3-carbonitrile, benzoate (1:1) and the corresponding free Bases, such as those represented by formula M on page 3 of patent application WO2004 / 052850 (1S,3S ,5S)-2-[(2S)-2-amino-2-(3-hydroxy-tricyclo[3.3.1.1 3, 7 ]dec-1-yl)-1-oxoethyl]-2-azabicyclo-[3.1.0]hexane-3 The compound BMS- is also known as BMS-carbonitrile (M') and its monohydrate (M"). 477118 is also known as saxagliptin.
[0025] Another preferred inhibitor is compound GS disclosed in WO03 / 002531 (Example 9). K23A, (2S,4S)-1-((2R)-2-amino-3-[(4-methoxyphenyl)phenyl]phenyl]- Dimethylsulfonyl]-3-methylbutanoyl)-4-fluoropyrrolidine-2-carbonite Also known as rill.
[0026] Other highly preferred DPP-IV inhibitors of the present invention are those disclosed in International Patent Application No. WO02 / 07 6450 (especially Examples 1 to 128), and Wallace T. Ashton (Bioorganic & Med and in particular compound 1 and the compound shown in Table 1. 1 and 2. Preferred compounds are those of the formula: [ka] Compound 21e (Table 1).
[0027] 3-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]thiazolidine The well-known P32 / 98 or P3298 (CAS number: 251572-86-8) is as follows: : [ka] 3-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]thio Azolidine and (2E)-2-butenedioic acid salts can be used as a (2:1) mixture. , and in the name of Probiodrug in WO 99 / 61431, and in Diabetes 47:1253-125 8 (1998), and also under the name of compound P93 / 01 described by the same company. do.
[0028] Other preferred DPP-IV inhibitors are disclosed in patent application WO02 / 083128. The most preferred DPP-IV inhibitors are those described in Example 1. to 13 and the compounds more specifically described in claims 6 to 10. Other preferred DPP-IV inhibitors are described in patent application WO2004 / 037169. and WO02 / 062764, in particular those described in Examples 1 to 48. Particularly preferred are examples 1 to 293 described on page 7 and in the patent application Ser. Compounds 3-, which are also described in WO 2004 / 024184, in particular in Reference Examples 1 to 4 (Aminomethyl)-2-isobutyl-1-oxo-4-phenyl-1,2-dihydro-6- Isoquinolinecarboxamide and 2-{[3-(aminomethyl)-2-isobutyl-4- phenyl-1-oxo-1,2-dihydro-6-isoquinolyl]oxy}acetamide .
[0029] Other preferred DPP-IV inhibitors are described in patent application WO03 / 004498, in particular The formula: [ka] and is also known as MK-0431 or sitagliptin.
[0030] Preferred DPP-IV inhibitors are also described in patent application WO2004 / 037181, in particular The compounds according to the invention are those described in the examples 1 to 33, and most preferably those described in the claims 3 to 5. Preferred DPP-IV inhibitors are N-substituted adamantyl-amino-acetyl-2-cyano Pyrrolidine, N-(substituted glycyl)-4-cyanopyrrolidine, N-(N'-substituted glycyl)- 2-cyanopyrrolidine, N-aminoacylthiazolidine, N-aminoacylthiazolidine, L-allo-isoleucyl thiazolidine, L-threo-isoleucyl pyrrolidine and L- Allo-isoleucylpyrrolidine, 1-[2-[(5-cyanopyridin-2-yl)amino] [ethylamino]acetyl-2-cyano-(S)-pyrrolidine and pharmaceutical salts thereof.
[0031] Particularly preferred is the formula: [ka] 1-{2-[(5-cyanopyridin-2-yl)amino]ethylamino}acetyl-2-acetate dihydrochloride (S)-Cyano-pyrrolidine (DPP728), in particular its dihydrochloride salt, and the compound of formula: [ka] (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidone Lysine (LAF237), and L-threo-isoleucyl thiazolidine (Pro Biodrug compound code: P32 / 98), MK-0431, GSK23A, BMS- 477118, 3-(aminomethyl)-2-isobutyl-1-oxo-4-phenyl-1, 2-Dihydro-6-isoquinolinecarboxamide and 2-{[3-(aminomethyl)-2- isobutyl-4-phenyl-1-oxo-1,2-dihydro-6-isoquinolyl]oxy} acetamide as well as optionally any pharmaceutical salts thereof.
[0032] DPP728 and LAF237 are highly preferred compounds, and specifically each As described in Example 3 of WO98 / 19998 and Example 1 of WO00 / 34241, The DPP-IV inhibitor P32 / 98 (see above) is specifically shown to inhibit Diabetes Mellitus 47 DPP728 and LAF237 are described in J. Immunol. 1998, 1253-1258. As described on page 20 of WO98 / 19998 or in WO00 / 34241 A preferred formulation for administration of LAF237 is described in U.S. Provisional Patent Application No. 6,313,663. It is described in No. 0 / 604274.
[0033] Particularly preferred are orally active DPP-IV inhibitors. In each case, particularly in the final products of the compound claims and examples, The subject matter, pharmaceutical formulations and claims are incorporated herein by reference in their entirety. It is expressly incorporated into this application.
[0034] DPP-IV inhibitor compounds, such as those of formula (I) and their corresponding pharma- ceutically acceptable derivatives The acid addition salt may be combined with one or more pharma- ceutically acceptable carriers and, optionally, one or more or more other conventional pharmaceutical adjuvants and administered enterally, e.g. Orally in the form of tablets, capsules, caplets, etc., or parenterally, e.g., intravenously; It can be administered in the form of a sterile injectable solution or suspension. The composition may be prepared by conventional means.
[0035] DPP-IV inhibitor compounds, such as those of formula (I) and their corresponding pharma- ceutically acceptable derivatives The acid addition salts of the compounds described herein are useful in treating conditions mediated by DPP-IV inhibition. The composition can be formulated into enteral and parenteral pharmaceutical compositions containing the amount of the substance. The article is in unit dosage form and such compositions include a pharma- ceutically acceptable carrier.
[0036] DPP-IV inhibitor compounds, including, for example, each of those under the scope and each of the examples of formula (I) in enantiomerically pure form, e.g. >98%, preferably >99%; can be administered together with the R enantiomer, e.g., in racemic form. The dosage ranges given above are Based on the amount of compound of formula (I) excluding the amount of the R enantiomer.
[0037] In view of its ability to inhibit DPP-IV, DPP-IV inhibitor compounds, such as those of formula (I) and their corresponding pharma- ceutical acceptable acid addition salts, which are mediated by DPP-IV inhibition. Based on the above and findings in the literature, the present invention is useful for treating conditions The compounds disclosed in the document are useful in treating insulin-dependent diabetes, arthritis, obesity, allografts and calcitonin. Tonin- is predicted to be useful in the treatment of conditions such as osteoporosis. In addition, GLP-1 and The role of glucagon-like peptides such as GLP-2 and DPP-IV inhibition Based on this association, the compounds disclosed herein may, for example, produce a sedative or anxiolytic effect. or attenuating the hormonal response to catabolic changes and stress following surgery. or in reducing mortality and morbidity after myocardial infarction, or in inhibiting GLP-1 and and / or in the treatment of conditions related to the above effects that may be mediated by GLP-2 levels. It is predicted to be useful.
[0038] More specifically, for example, DPP-IV inhibitor compounds, such as those of formula (I) and the like The corresponding pharma- ceutically acceptable acid addition salts of the above are effective in inhibiting the early insulin response to oral glucose loading. These improve the response to insulin and are therefore useful in treating non-insulin dependent diabetes mellitus.
[0039] DPP-IV inhibitor compounds useful in the present invention, particularly compounds of formula I, IA or IB is hygroscopic, has stability problems, and is essentially non-compression moldable. Robust formulation with acceptable in vitro dissolution profile and good stability of the active ingredient There is a need to provide a free-flowing and cohesive composition that can be compressed into tablets. Tablets are solid dosage pharmaceutical forms containing the active ingredient, with or without a suitable filler. It can be defined as the active ingredient and the additive used to aid processing and improve product properties. The composition is produced by compression or compression molding of a formulation containing specific excipients selected for the purpose of The tablets may be coated or uncoated and are made from powdered crystalline material. It is made by mixing various diluents, binders, disintegrants, lubricants, glidants, and many other additives. Coloring agents may be included if desired. The excipients used are classified according to the function they perform. For example, glidants can be used to improve the flowability of the powder mix in the hopper and into the tablet die. can be improved.
[0040] Tablets have been widely used since the late 19th century, and the majority of pharmaceutical dosage forms are tablets. The popularity of tablets as a dosage form is primarily due to their ease of production, low cost, and Other reasons include stability of the drug product, convenience of packaging, transportation and distribution. Tablets offer the patient or consumer convenience of administration, ease of accurate dosing, small size, portability, bland taste, ease of administration, and elegance and distinctiveness. Provides a stylish appearance.
[0041] Tablets may be plain, film or sugar-coated, divided, embossed, multi-layered or It can be made in various sizes, shapes and colors. The tablet is swallowed, It can be chewed or dissolved in the mouth or under the tongue. Sterile tablets are usually used for parenteral solutions and subcutaneous implants. It is used in.
[0042] In addition to the active or therapeutic ingredient, tablets contain a number of inactive materials known as excipients. It can be classified according to the role it plays in the final tablet. The composition includes a filler, a binder, a lubricant and a glidant. Other excipients that provide character are colorants and, in the case of chewable tablets, flavoring agents. Without the aid of an additive, most drugs and pharmaceutical ingredients cannot be directly compressed into tablets. This is mainly due to the poor flow and cohesive properties of most drugs. In addition to the formulation, it imparts good flow and compressibility characteristics to the material being compressed. It is added through pre-processing steps such as wet granulation, slugging, spray drying, spheronization or crystallization. It is given.
[0043] Lubricants typically prevent the tableting material from sticking to the punches and aid in the tablet compression process. Added to minimize resistance and allow the compressed tablet to be removed from the die. Such lubricants are commonly included in the final tablet mix, usually in an amount of about 1% by weight.
[0044] Other desirable characteristics of an excipient include: High compressibility allowing for the creation of strong tablets at low compression forces; imparting cohesive qualities to powdered materials; acceptable rate of decay; Good flow properties that can improve the flow of other excipients in the formulation; and Cohesiveness (prevents the tablet from crumbling during processing, shipping and handling).
[0045] There are three commercially important methods for making compressed tablets: wet granulation, direct compression, and dry granulation. The manufacturing method and type of excipients affect the rapid production of tablets. They are selected to impart desirable physical characteristics to the tablet formulation that allow for rapid compression. Afterwards, the tablets are processed to meet many further requirements such as appearance, hardness, disintegration ability and acceptable dissolution profile. The selection of fillers and other excipients should be based on the chemical and physical properties of the drug. The preformability depends on the formulation and physical properties, the nature of the mixture during processing and the properties of the final tablet. Simulation studies were performed to determine the chemical and physical compatibility of the active ingredient with the proposed excipients. Determine gender.
[0046] The properties of the drug, its dosage form and the economics of the operation will determine the selection of the best method for tableting. Both wet granulation and direct compression are commonly used in tablet development.
[0047] One of the components, either the drug or the diluent, has sufficient cohesive properties to be tableted. In this case, dry granulation can be used. The method involves blending, slugging the ingredients, drying and sieving. It consists of separating, lubricating and compressing.
[0048] Wet granulation is used to convert the powder mixture into granules with suitable flow and cohesive properties for tableting. The procedure involves mixing the powders in a suitable mixer, followed by mixing under shear to obtain granules. It consists of adding the granulation liquid to the powder mix. The wet mass is then sieved through a suitable sieve and Alternatively, the wet mass is dried by drying in a tray or fluidized bed. The entire process includes weighing, dry powder blending, wet granulation, This includes drying, grinding, lubricating and compressing.
[0049] Generally, powders have sufficient adhesive or cohesive properties to form firm, rigid granules. Usually, most powders have poor cohesive properties and binders are required to bind the powder particles together. Heat and moisture sensitive drugs are usually manufactured using wet granulation. Due to the high manufacturing costs, the number of processing steps and processing time are problems. Wet granulation also reduces the compressibility of some pharmaceutical excipients, such as microcrystalline cellulose. It is also known to lower
[0050] Direct compression is a process in which powder materials are compressed directly into a drug without changing its physical and chemical properties. It is considered to be a relatively rapid method when the active ingredient(s), direct compression extrusion The excipients and other auxiliary substances such as glidants and lubricants are mixed into the tablet prior to compression into tablets. Blend in an in-shell blender or similar low shear device. This type of blending is known as "pharmaceutical was considered essential to produce an "acceptable" dosage form. Some believe that the manner in which a lubricant is added to a formulation must be carefully controlled. Therefore, lubricants are usually added to granules by gentle mixing. It is also believed that prolonged blending times can substantially affect the hardness and disintegration time of the resulting tablets. Excessive mixing of the lubricant with the granule components causes the granules to become waterproof and the granules become difficult to compress. For these reasons, direct compression dosage forms may be used without the use of ethylene glycol or propylene glycol. No high shear mixing conditions were used to prepare the product.
[0051] Advantages of direct compression include uniformity of blend and fewer manufacturing steps involved, i.e. The entire process involves weighing, mixing and compressing the powders, hence low cost; excluding heat and moisture, and the main particles With dissociation and physical stability.
[0052] Pharmaceutical manufacturers are increasingly using direct granulation over wet or dry granulation methods due to the benefits of quick processing time and costs. Direct compression is usually preferred because the drug or active ingredient is not pharma- ceutical Limited to those circumstances in which the tablet has the physical characteristics required to form an acceptable tablet. However, many ingredients do not have the necessary properties before direct compression can be used. Therefore, one or more excipients must often be combined with the active ingredient. Because each excipient added to a formulation increases the size of the final tablet, manufacturers often Formulations containing low doses of active ingredient per tablet are restricted to the use of direct compression. .
[0053] Solid dosage forms containing high doses of drug (i.e., the drug itself accounts for a significant portion of the total compressed tablet weight) The drug itself has sufficient physical properties, e.g., cohesion, for the directly compressed component to be compressed. If the drug has the desired properties and if it is properly formulated, it can only be directly compressed.
[0054] By way of example, DPP-IV inhibitors, such as those of formula (I), are considered high-dose drugs. The current tablet formulations contain DPP-IV inhibitors in the range of 70-85% by weight per tablet. This high dose drug combined with its rather poor physical properties for close compression makes it difficult to produce the final tablet. In addition, the active ingredient may be granulated by wet granulation. Another factor that works against the use of .alpha.-methylbutyric acid is its poor stability in the presence of water.
[0055] Another limitation of direct compression as a method of tablet production is the potential size of the compressed tablets. When the amount of active ingredient is large, the pharmaceutical formulator must determine the size of the formulation that will be tolerated by the desired amount of active ingredient. One may choose to wet granulate the active ingredient with other excipients to obtain tablets. The method of granulation contributes to the desired physical properties of the tablet, so the fillers, binders, and other additives required for wet granulation are The amount of agent or other excipients required is less than that required for direct compression.
[0056] Despite the advantages of direct compression, such as reduced processing time and costs, wet granulation is still a popular method for producing solid dosage forms. Wet granulation is widely used in the industry to produce pharmaceutical formulations. Wet granulation has more opportunities to overcome any problems associated with mechanical properties. This is often preferred over the required solubility required to obtain an acceptable solid dosage form. The present invention provides a material having flow and cohesive properties that are
[0057] The popularity of wet granulation compared to direct compression is based on at least three advantages. First, wet granulation The granules provide a material that compresses with better wetting properties, especially for hydrophobic drugs. The addition of excipients makes the surface of hydrophobic drugs more hydrophilic, reducing disintegration and dissolution problems. Second, all granules usually contain the same amount of drug, resulting in uniform content of the solid dosage form. Finally, separation of the drug(s) from the excipients is avoided. will be done.
[0058] Segregation can be a potential problem in direct compression. The size and shape of the particles comprising the granules being compressed The shape is optimized through the wet granulation process. This is because when dry solids are wet granulated, the particles become spherical. This is because the binder "glues" the particles together so that they agglomerate into shaped granules.
[0059] Because there is a significant amount of metformin in the formulation of the present invention, the size and The composition and shape of the composition allow for easy oral administration to patients and for easy administration of the composition to patients that meets all the requirements described herein. Therefore, it is difficult for manufacturers to manufacture high-dose DPP-IV inhibitors and The technology and pharmaceutical formulations that allow the production of toformin combination tablets (high drug load) are There is a need in the industry. High dose DPP-IV inhibitors and metformin tablets are preferred. or with a limited number and amount of pharmaceutical excipients to reduce tablet size. It must meet all the requirements listed in. DISCLOSURE OF THEINVENTION
[0060] A free-flowing, cohesive tablet powder that can be easily granulated or compressed into tablets. It is an object of the present invention to provide a formulation comprising a DPP-IV inhibitor and metformin in the form It is.
[0061] To an acceptable dissolution profile and acceptable degrees of hardness, friability and fragmentation DP, which has resistance to 100% water, as well as suitable disintegration time and high stability of the active ingredient in the tablet. To provide a high drug load tablet in a unit dosage form comprising a P-IV inhibitor and metformin It is a further object of the present invention.
[0062] Vildagliptin is sensitive to moisture and therefore a product stability issue. In order to overcome this problem, the applicant has To obtain desirable tablet properties, e.g. hardness, friability, and to improve the stability of the active ingredient. formulations (with selected excipients) and direct compression A method (to avoid wet granulation) was developed.
[0063] Metformin is typically manufactured by wet granulation with a high drug load and processed It is known that roller compaction is very difficult to achieve due to poor compaction properties. It is also known that direct compression is not acceptable for such high drug load formulations. Not recommended. Poor compressibility and tablet friability are known problems and therefore This was another major priority during development. Other issues were: High dose of metformin, hence large pill and low drug load of LAF237. · Difficulty in processing Met. · Met is a wet granulation process, and moisture is known to be detrimental to LAF.
[0064] Therefore, diabetic patients should be given between 25 and 100 mg of vildagliptin and 1000 mg of mg of metformin in tablets of acceptable size and with good tablet properties, e.g. There is an unmet need to provide compressed tablets having the desired hardness, friability and stability of the active ingredient. stomach.
[0065] DP with high drug loading to reduce tablet size and active ingredient remains stable It is an object of the present invention to provide a unit dosage tablet comprising a P-IV inhibitor and metformin. This is a further objective. A formulation comprising a DPP-IV inhibitor and metformin or any salt thereof, It is a further object of the present invention to provide a method for producing tablets. The present invention can be compressed into tablets and has sufficient particle size, hardness, stability, and rapid disintegration. DPP-IV inhibitors in tablet-ready powder form with intermediate and acceptable dissolution patterns and Formulations comprising metformin are provided.
[0066] In addition to the active ingredient, tablet powders contain a number of inert materials known as excipients. They can be classified according to the role they play in the final tablet. The finished tablet contains the following additives: binder or diluent, lubricant, disintegrant and glidant. Other excipients which impart physical properties are colourants and, in the case of chewable tablets, flavouring agents. Excipients are typically added to formulations to impart good flow and compression properties to the material being compressed. do.
[0067] A preferred formulation of the present invention is the following: an active ingredient, a DPP-IV inhibitor compound, and metformin. the active ingredient, as well as a binder; Examples of pharma- ceutically acceptable binders include, but are not limited to, starch; cellulose; and its derivatives, such as microcrystalline cellulose, hydroxypropyl cellulose, ethyl cellulose and hydroxypropyl methylcellulose; sucrose; dextran corn syrup; polysaccharides; and gelatin. Binders include, for example, From about 1% to about 40% by weight of the composition, preferably from 1% to 30% or from 1% to 20% It may be present in an amount of 5% or 1% to 20%.
[0068] Optionally, one, two, three or more diluents may be added to the formulations of the present invention. Examples of pharma- ceutically acceptable bulking agents and pharma- ceutically acceptable diluents include, but are not limited to, Powdered sugar, sugar for compression, dextrates, dextrin, dextrose, etc. cellulose, lactose, mannitol, microcrystalline cellulose, powdered cellulose, sorbitol, Examples of bulking agents and / or diluents include sucrose and talc. It may be present in an amount of about 15% to about 40% by weight. Preferred diluents include fibrous plant materials. The alpha-cellulose obtained as a pulp from After hydrolysis, the hydrated cellulose is filtered and The aqueous slurry is then spray dried to form dry porous particles of broad particle size distribution. Suitable microcrystalline cellulose has an average particle size of about 20 nm to about 200 nm. Crystalline cellulose is available from several sources. Avicel PH101, Avicel PH102, Avicel PH103, Avicel PH201, Avicel PH302, Avicel PH403, Avicel PH501, Avicel PH601, Avicel PH701, Avicel PH801, Avicel PH901, Avicel PH101, Avicel PH102, Avicel PH103, A Particularly preferred in the practice of the present invention are surface area Avicel PH102 has the lowest pore structure and is preferably a microcrystalline cell. The sugar is present in the tablet formulation in an amount of about 25% to about 70% by weight. Another preferred embodiment of this ingredient is A preferred range is from about 30% to about 35% by weight; yet another preferred range is from about 30% to about 35% by weight. About 32% by weight. Another diluent is lactose. Preferably, lactose is added prior to formulation. The lactose is milled to have an average particle size between about 50 μm and about 500 μm. Present in the formulation in an amount of about 5% to about 40% by weight, and about 18% to about 35% by weight and most preferably from about 20% to about 25% by weight.
[0069] Optionally, one, two, three or more disintegrants may be added to the formulation of the present invention. Examples of pharma- ceutically acceptable disintegrants include, but are not limited to, starch; Earth; cellulose; alginic acid; gums; cross-linked polymers, e.g. cross-linked polyvinylpyrrolidone, cross-linked Cross-linked calcium carboxymethylcellulose and cross-linked sodium carboxymethylcellulose Disintegrants include, for example, gum; soy polysaccharides; and guar gum. % to about 20% by weight, for example about 5% to about 10% by weight, for example about 7% by weight. Disintegrants are also an optional but useful component of tablet formulations. Disintegrants are included to ensure that the disintegrant has an acceptable disintegration rate. Typical disintegrants include Starch derivatives and salts of carboxymethylcellulose are included. Starch glycols Sodium phosphate is the preferred disintegrant for this formulation. Preferably, the disintegrant is present in the tablet formulation at about 0.5% by weight. % to about 10% by weight, and may be from about 1% to about 4% by weight; and Most preferably, it may be from about 1.5% to about 2.5% by weight.
[0070] Optionally, one, two, three or more lubricants may be added to the formulations of the present invention. Examples of pharma- ceutically acceptable lubricants and pharma-ceutically acceptable glidants include: Non-limiting examples include colloidal silica, magnesium trisilicate, starch, talc, Tricalcium phosphate, magnesium stearate, aluminum stearate, stearate Calcium phosphate, magnesium carbonate, magnesium oxide, polyethylene glycol, powder Lubricants include, for example, about 0.5% of the composition. The glidants may be present in an amount of from 1% to about 5% by weight; whereas the glidants may be present in an amount of, for example, about 0.1% by weight. Lubricants may be present in an amount of from about 10% by weight. Lubricants typically help prevent tablet material from sticking to the punches. to prevent the tablet from coming into contact with the tablet, to minimize resistance during tablet compression, and to facilitate removal of the compressed tablet from the die. Such lubricants are generally added in amounts of less than 1% by weight in the final tablet mix. Lubricant components can be hydrophobic or hydrophilic. Examples of such lubricants include stearyl alcohol, glyceryl ... These include magnesium stearate, talc and magnesium stearate. The foam reduces the friability between the die wall and the tablet mix during tablet compression and extrusion. This helps prevent tablet sticking to punches and dies. Magnesium stearate It also aids in the flow of powder into the hopper and into the die. It is 450-550 microns It has a particle size range of 1.00-1.80 g / ml and a density range of 1.00-1.80 g / ml. It is stable and Magnesium stearate, a preferred lubricant, is also Also used in the formulation. Preferably, the lubricant is present in an amount of from about 0.25% by weight to about 6% by weight in the tablet formulation. % by weight; and preferably from about 0.5% to about 4% by weight; and most preferably or at a level of about 0.1% to about 2% by weight. Other possible lubricants include talc, Polyethylene glycol, silica and hydrogenated vegetable oil. Lubricants are not present in the formulation but are added to the die or punch rather than directly to the formulation. is sprayed onto the
[0071] Optionally, corn starch, calcium phosphate, calcium sulfate, stearic acid Calcium, Magnesium Stearate, Stearic Acid, Glyceryl Mono- and Di-Stearates cellulose, sorbitol, mannitol, gelatin, carboxymethylcellulose, methylcellulose Lubricant, alginic acid, dextran, acacia gum, karaya gum, locust bean gum other conventional solid fillers such as natural or synthetic gums such as gum, tragacanth, etc. Carriers, diluents, binders, lubricants, disintegrating agents, coloring agents and flavoring agents may also be used.
[0072] Further examples of useful excipients that can be optionally added to the compositions of the present invention include the Ha ndbook of pharmaceutical excipients, 3rd edition , Edited by AHKibbe, Published d by: American Pharmaceutical Association, Washington DC, ISBN: 0-917330-96-X, or Handbook of Pharmaceutical Excipients (4 th edition), Edited by Raymond C Ro we - Publisher: Science and Practice (which are hereby incorporated by reference). )
[0073] Thus, in a first aspect, the present invention provides a composition comprising between 50 and 98% by weight, based on dry weight, Between 0% and 96% by weight, Between 60% and 98% by weight, Between 60% and 96% by weight %, or between 70 and 98% by weight, between 70 and 96% by weight, or between 80 and 98% by weight % or between 80 and 96% by weight of the active ingredient. , wherein the active ingredient is a DPP-IV inhibitor, preferably vildagliptin and metformin or in each case a pharma- ceutically acceptable salt thereof.
[0074] In a second aspect, the present invention provides a composition comprising between 50 and 98% by weight, based on dry weight, between 60% and 98% by weight, between 60% and 96% by weight, or between 70 and 98% by weight, between 70 and 96% by weight, preferably between 80 and 98% by weight. High-dose loaded tablets or direct compression tablets containing between 80 and 96% by weight of the active ingredient The present invention relates to a compressed tablet, wherein the active ingredient is a DPP-IV inhibitor, preferably vildagliptin and and metformin or a pharma- ceutical acceptable salt thereof in each case.
[0075] A composition or tablet as described hereinbefore, wherein metformin is in the form of granules. The metformin is in the form of a granule, and the granule contains at least one pharma- ceutically acceptable A composition or tablet as described herein above containing an excipient. As described hereinabove, the metformin is in the form of granules, and the granules contain a binder. The composition or tablet as described above. As described hereinabove, the metformin is in the form of granules containing between 1 and 25% binder. or tablets (1 to 25% of the weight of the granules on a dry weight basis). Metformin granules and vildagliptin and optionally at least one pharma- ceutically acceptable A tablet as described herein obtained by direct compression with excipients that are
[0076] Between 1 and 25% by weight of binder, preferably between 1 and 20% by weight, based on dry weight , preferably between 1 and 12% by weight, between 2.9 and 11% by weight, or between 6.5 and 9.5% by weight. % by weight, or between 7.5 and 17.5% by weight, or between 12.5 and 17.5% by weight A composition or tablet as described herein above comprising a pharma- ceutically acceptable binder. At least one pharma- ceutically acceptable lubricant excipient is preferably added to the composition or Between 0.1% and 5% by weight of the tablet, between 0.1% and 2% by weight, or between 0.1% and 5% by weight of the tablet. Between 0.1% and 1% by weight of the composition or tablet. The composition or tablet as described hereinbefore, wherein the lubricant is magnesium stearate. 4. A pharmaceutical composition or tablet as described herein above, which is a medicament.
[0077] The binder is starch; cellulose and its derivatives, such as microcrystalline cellulose, hydrolyzed cellulose, etc. Hydroxypropyl cellulose, hydroxyethyl cellulose and hydroxypropyl methyl cellulose cellulose; sucrose; dextrose; corn syrup; polysaccharides; and gelatin. A pharmaceutical composition or tablet as described herein, selected from the group consisting of cinnamon, cinnamon, cinnamon powder ...
[0078] The binder is cellulose and its derivatives, preferably hydroxypropyl cellulose (H PC). The ratios described herein are based on the DPP-IV inhibitor, metformin and excipients, e.g. Obtained on a dry weight basis with respect to binder.
[0079] A pharmaceutical composition as described herein in the form of a unit dosage form. The unit dosage form comprises: Any type of tablet formulation such as capsules, tablets (preferably direct compressed tablets), granules, chewable tablets, etc. It is a pharmaceutical dosage form. In a further aspect, the present invention provides as an active ingredient i) between 0.5 and 35%, or between 1.5 and 35%, preferably between 0.5 and 20% or between 1.5 and 20% DPP-IV inhibitor, preferably vildagliptin or Pharmacologically acceptable salts thereof; ii) between 65 and 98.5%, preferably between 80 and 98.5%, of metformin; or Pharmacologically acceptable salts thereof; In a tablet or pharmaceutical composition comprising: in the form of granules containing from 1 to 25% by weight of the granules on a dry weight basis; or As an active ingredient i) between 0.5 and 35%, or between 1.5 and 35%, preferably between 0.5 and 20% or between 1.5 and 20% DPP-IV inhibitor, preferably vildagliptin or Pharmacologically acceptable salts thereof; ii) between 65 and 98.5%, preferably between 80 and 98.5%, of metformin; or Pharmacologically acceptable salts thereof; A high drug load tablet or a high drug load pharmaceutical composition as described herein comprising: Here, metformin is prepared in a granule containing between 1 and 25% binder (based on dry weight of the granule). 1 to 25% by weight.
[0080] granules are between 1 and 20% by weight, preferably between 3 and 13% by weight, based on the dry weight; Between 4.9 and 12% by weight, or between 7.5 and 10.5% by weight, or between 7.5 and 17. 5% by weight, or between 12.5 and 17.5% by weight of a pharma- ceutically acceptable binder. A tablet or pharmaceutical composition as described herein. The binder is starch; cellulose and its derivatives, such as microcrystalline cellulose, hydrolyzed cellulose, etc. Hydroxypropyl cellulose, hydroxyethyl cellulose and hydroxypropyl methyl cellulose cellulose; sucrose; dextrose; corn syrup; polysaccharides; and gelatin. A tablet or pharmaceutical composition as described herein selected from the group consisting of chin.
[0081] The binder is cellulose and its derivatives, preferably hydroxypropyl cellulose (H PC). The compositions and tablets claimed herein preferably contain at least one pharma- ceutical Contains acceptable excipients. Such as conventional binders, diluents, disintegrants, solid fillers or carriers as described herein. At least one, e.g., one, two, three or four, further conventional pharma- ceutically acceptable Excipients such as those listed below may be added to the formulations described herein as desired. The formulation may be 25% or 20% by weight or preferably 17.5% or less by weight based on dry weight. or 15% or 11% by weight of a pharma- ceutically acceptable excipient, including a binder. Contains.
[0082] Between 1 and 12% by weight of the composition / tablet based on dry weight, preferably between 2.9 and 11 % by weight, or between 6.5 and 9.5% by weight, or between 7.5 and 17.5% by weight, or between 12.5 and 17.5% by weight of a pharma- ceutically acceptable binder, and optionally a drying agent. Between 0.1 and 10% by weight of additional pharma- ceutically acceptable excipients (one, two or more or more), e.g. between 0.1% and 2% by weight of a lubricant (e.g. stearic acid Magnesium). Preferably, The granules are between 3 and 13% by weight, between 4.9 and 12% by weight, or 7. Between 5 and 10.5% by weight, or between 7.5 and 17.5% by weight, or between 12.5 and 17 0.5% by weight of a pharma- ceutically acceptable binder.
[0083] Between 50 and 98% by weight, between 70 and 98% by weight on a dry weight basis, or preferably The present invention relates to a composition comprising between 80 and 98% by weight, or between 80 and 96% by weight, of the active ingredient. wherein the active ingredient is preferably vildagliptin. The present invention is directed to a method for treating rheumatoid arthritis, comprising administering to the patient an effective amount of metformin and metformin, or in each case a pharma- ceutically acceptable salt thereof.
[0084] As described herein, comprising at least one additional pharma- ceutically acceptable excipient. A tablet or pharmaceutical composition. Further pharma- ceutically acceptable excipients may be fillers, binders or diluents, lubricants, disintegrants and and a glidant. Other excipients that give the drug its physical properties are colorants and, in the case of chewable tablets, flavorings. be.
[0085] Preferably between 0.1% and 5% by weight of the composition, or 0.1% to 2% by weight A small amount of lubricant, most preferably between 0.5% and 1.5% by weight of the composition / tablet. A tablet as described herein containing at least one further pharma- ceutically acceptable excipient. Agent or pharmaceutical composition. Between 0.1 and 5%, preferably between 0.1 and 2%, or between 0.5 and 1.5%. A tablet or pharmaceutical composition as described herein comprising magnesium tearate. A tablet or medicament as described herein, wherein the lubricant is magnesium stearate. composition. The metformin granules described herein are produced by wet or melt granulation using a binder. The tablet or pharmaceutical composition as described above.
[0086] Metformin granules are mixed with water or ethanol, isopropanol, acetic acid, and ethyl acetate by wet granulation. A solvent selected from organic solvents such as ethyl acetate, glycofurol, and propylene glycol is used. The tablet or pharmaceutical composition as described herein is produced by The tablet or tablet formulation as described herein, in which metformin granules are produced by melt granulation. Pharmaceutical Compositions. The Melt Granulation Process is "Hot-melt Extrusion Technique": A Review; Iranian Jou Journal of Pharmaceutical Research 3:3-16(2004);Rina Chokshi et al. or review Joerg Breitenbach “Melt extrusion: from process to drug delivery technology”: Europ ean Journal of Pharmaceutics and Biopharmaceutics 54:107-117(2002) (both cited) and US Pat. No. 6,399,623, which are incorporated herein by reference.
[0087] A tablet or medicament as described herein, in which vildagliptin is present in bulk form. composition. DPP-IV inhibitors, preferably vildagliptin, between 0.5 and 35%, or 1. Between 5 and 35% i.e., the active ingredient from DPP-IV inhibitor + metformin A tablet or formulation as described herein. The vildagliptin is in the form of particles, wherein at least 40%, preferably 60%, Most preferably, 80% and even more preferably 90% of the vildagliptin is less than 250 μm. or preferably having a particle size distribution between 10 and 250 μm, or at least In the present invention, 25% or at least 35% of the particle size distribution is between 50 and 150 μm. A tablet or pharmaceutical composition as described.
[0088] A tablet or pharmaceutical composition as described herein, wherein vildagliptin is in the form of particles. thing. The tablets or tablets as described herein are prepared by solvent granulation. Or a pharmaceutical composition. The solvent used in the granulation process is preferably ethanol, isopropanol, ethyl acetate, As described herein, selected from glycofurol or propylene glycol Tablet or pharmaceutical composition. Contained in a capsule or in the form of a tablet, preferably a compressed or directly compressed tablet. The pharmaceutical composition as described herein is in the form of a tablet. For example, a film coating of Opadry premix can be applied. A pharmaceutical composition as described herein, wherein the formulation corresponds to one of the layers of a bilayer or trilayer tablet. A preferred bilayer tablet according to the invention comprises a first layer containing the formulation of the invention and a further layer as the second layer. Metformin or a glitazone (e.g., pioglitazone or rosiglitazone or any This includes pharmaceutical preparations of the compound (or its pharmaceutical salt, if desired).
[0089] Glitazones, such as pioglitazone or rosiglitazone, or sulfonylureas Insulin secretagogues such as glipizide, glyburide and amaryl; Insulinotropic sulfonylurea receptor ligands such as tinides, e.g. nateglinide Formulations according to the invention containing further active ingredients which are glitazones and repaglinide. The sulfonylurea is added to metformin granules (metformin + binder + glitazone or metformin + binder + glitazone). toformin + binder + sulfonylurea), or with LAF237 drug substance.
[0090] The formulation according to the invention corresponds to one layer and the glitazone, e.g. pioglitazone, loglitazone, Bilayer or triple layer tablets with ciglitazone or a sulfonylurea present in the second layer. Such as conventional diluents, disintegrants, solid fillers or carriers as described herein. Additional conventional pharma- ceutically acceptable excipients (at least one, e.g., one, two, three or more) One or four excipients may be added to the formulations described herein, if desired. Preferably, the formulation comprises 25%, 20%, 17.5 or 13% by weight based on dry weight. % of a pharma- ceutically acceptable binder, including the binder present in the metformin granules. It contains excipients that are
[0091] Most preferably, the pharmaceutical composition contains between 0.1 and 5%, preferably between 0.5 and 3%, or between 0.5 and 1.5% of a pharma- ceutically acceptable lubricant, preferably magnesium stearate. Contains sodium. The composition is selected from microcrystalline cellulose such as Avicel PH102 and lactose. The composition may contain one or two diluents of choice. In this application, reference to a pharma- ceutically acceptable disintegrant means at least one disintegrant. It also extends to mixtures of two or three disintegrants. In this application, reference to a pharma- ceutically acceptable lubricant means at least one lubricant. It also extends to mixtures of two or three lubricants.
[0092] The preferred DPP-IV inhibitor is LAF237 and the preferred diluent is microcrystalline cellulo cellulose or lactose or preferably a combination of microcrystalline cellulose and lactose. The preferred disintegrant is sodium starch glycolate, and the preferred binder is The binders are cellulose type binders (cellulose and its derivatives), such as HPC, and are preferred. A preferred lubricant is magnesium stearate.
[0093] The above-mentioned formulations are particularly suitable for use as pharmaceutical tablets, e.g. compressed or directly compressed tablets, caplets, The necessary physical properties as applied to the production of capsules or capsules and as required by those skilled in the art. , dissolution and drug release profiles. Thus, in a further aspect, the present invention provides For the manufacture of pharmaceutical tablets, caplets or capsules, inter alia, by granulation, direct compression and and the use of any of the above-mentioned formulations for dry granulation (slugging or roller compaction). Regarding.
[0094] The above formulations are also particularly useful for producing tablets, particularly compressed or direct compressed tablets. . In particular, the tablets obtained using the above formulation have low friability problems, very good breaking strength, consistency, improved manufacturing robustness, optimal tablet thickness to tablet weight ratio (direct compression tablets) , Low water content in formulations, especially direct compression tablets, British Pharmacopoeia (1988), Good Dispersion Quality It has good dispersion decay time due to y.
[0095] The present invention involves blending, granulation and compression. The selection of the grade of excipient also determines the homogeneity of the powder mixture. Taking into account the particle size maintained within a range that allows uniformity of quality and active ingredient content. It prevents the powder from segregating in the hopper during compression. The advantages of using the formulation of the present invention are: It is this that gives the powder mixture compressibility, cohesiveness and flowability. In addition, compression Offers competitive unit production costs, shelf life, rejects heat and moisture, and disaggregates primary particles , allowing for physical stability and ensuring particle size uniformity.
[0096] The described advantages of the claimed compositions are also achieved by, for example, roller compaction or wet granulation, compression, and is very useful for direct compression or for filling into capsules. In developing the pharmaceutical compositions described herein, Applicant has: i) The particles containing the DPP-IV inhibitor are less than 250 μm, preferably between 10 and 250 μm. and / or ii) After one week at 25°C and 60% indoor humidity (RH), the water content of the tablets is less than 10%. ; In this case, compressed tablets, especially direct compressed tablets, have been found to be particularly advantageous.
[0097] Thus in a further aspect (a) the invention relates to a pharmaceutical formulation or For compressed tablets, the dispersion contains a DPP-IV inhibitor in free or acid addition salt form, preferably Preferably, the tablet contains particles containing LAF237, wherein at least 60% of the particle size distribution in the tablet , preferably 80%, and most preferably 90% are less than 250 μm or preferably 1 Between 0 and 250 μm.
[0098] The present invention relates to a pharmaceutical formulation or compressed tablet as described herein, wherein the dispersion is Particles containing a DPP-IV inhibitor, preferably LAF237, in free form or in acid addition salt form wherein at least 60%, preferably 80%, and most preferably 100% of the particle size distribution in the tablet is Preferably 90% is greater than 10 μm.
[0099] The term "wherein metformin is in the form of granules" refers to the DPP-IV inhibitor being This means that it is not present in granules containing lumin. The term "wherein at least 60%, preferably 80% and most preferably 90%" is at least 60%, preferably at least 80% and most preferably at least 90% Means %. The term "wherein at least 25%, preferably 35% and most preferably 45%" is at least 25%, preferably at least 35% and most preferably at least 45% Means %.
[0100] In particular, the present invention relates to a pharmaceutical formulation or compressed tablet as described herein, The dispersion contains a DPP-IV inhibitor, preferably LAF237, in free or acid addition salt form. wherein at least 25% of the particle size distribution in the tablet, preferably 35% and and most preferably 45% are between 50 and 150 μm.
[0101] In a second aspect, the present invention relates to a pharmaceutical formulation or compressed tablet as described herein. wherein the dispersion contains a DPP-IV inhibitor in free or acid addition salt form, preferably LAF 237, wherein: i) at least 60%, preferably 80% and most preferably 90% of the particle size distribution in the tablet % is less than 250 μm, preferably between 10 and 250 μm; ii) After 1 week at 25°C and RH 60%, the water content of the tablets is less than 10%.
[0102] Preferably, the present invention relates to a pharmaceutical formulation or compressed tablet as described herein, The dispersion contains a DPP-IV inhibitor in free form or in acid addition salt form, preferably LAF23. 7. The method of claim 1, further comprising: i) at least 25%, preferably 35% and most preferably 45% of the particle size distribution in the tablet % are between 50 and 150 μm; ii) after 1 week at 25°C and 60% RH the water content of the tablet is less than 10%; or After 1 week at 25°C and 60% RH, the water content of the tablets is less than 5%.
[0103] Preferably, the DPPIV particles, particularly the LAF237 particles, inhibit DPPIV by more than 70%. agent, most preferably greater than 90% or 95%, and even more preferably greater than 98%. Includes more than 100 DPPIV inhibitors. Preferably, the LAF237 particles are greater than 70% LAF237, most preferably 90% or more than 95%, and even more preferably more than 98% LAF237 The selected particle size distribution of DPPIV inhibitors, especially LAF237, ensures optimal compression of tablets. It has been found to be particularly important to provide
[0104] Preferred excipients with suitable particle size distributions are described, for example, in the Handbook of Pharmaceutical Excipi ients(4 th edition), Edited by Raymond C Rowe - Publisher: Science and Practice You can choose from. The particle size of the drug, e.g. LAF237, can be adjusted by crystallization, drying and / or grinding / sieving (non- Particle size is controlled by roller compaction and milling / sieving. The production of precise particle sizes is well known and is described in the "Pharmaceutical utical dosage forms: volume 2, 2nd edition, Ed.: HALieberman, L.Lachman, JBS chwartz (Chapter 3: SIZE REDUCTION)" in the art.
[0105] A method for obtaining a suitable LAF237 particle size is described in patent application WO2005 / 067976. (which is incorporated herein by reference). Numerous particle sizes have been studied, and the specific particle size ranges described herein are believed to be suitable for compaction. Provides good results for shape.
[0106] Particle size distribution estimation by analytical sieves: sieve analysis, photon correlation spectroscopy, procedures well known to those skilled in the art, or laser diffraction (international standard ISO 13320-1), or electronic sensors. Measure particle size distribution using precipitation zone, light obstruction, sedimentation or microscopy. One of the oldest methods for classifying powders according to their particle size distribution is sieving. and is described in any analytical chemistry textbook or in the United States Pharmacopeia (USP) publication USP- NF(2004, Chapter 786(The United States Pharmacopeial Convention, Inc., Rockville, MD) (which describes the U.S. Food and Drug Administration (FDA) legally enforceable standards) The techniques used are described in the art, for example by Pharmaceutical d osage forms: volume 2, 2nd edition, Ed.: HALieberman, L.Lachman, JBSchwartz is a good example, which also mentions further methods (page 187). Examples include: electronic sensing zones, light obstruction, air penetration, and precipitation in gases or liquids.
[0107] In air jet sieving measurement of particle size, air is blown upward through a rotating slit and a sieve. At the same time, negative pressure is applied to the bottom of the sieve, which collects the fine particles. The single sieve is used in series to obtain a finer final product of particle size distribution. Particle size analysis and average particle size measurement are carried out by extracting particles from the object. For further details, see "Particle Size Measurement", 5th Ed., p 178, vol. 1; T. Allen, C see also Hapman & Hall, London, UK, 1997. Thus, those skilled in the art are familiar with such particle size measurements. is of a conventional nature.
[0108] The water content of the tablets was determined using the loss on drying method or the Karl Fischer method, both of which are methods well known to those skilled in the art. The amount can be measured (e.g. loss on drying by thermogrametry) (Water content can be measured by any analytical method.) Such methods are well known and can be used in any analytical method. Textbook (JA Dean, Analytical Chemistry Handbook, Section 19, McGraw-Hill, New York rk, 1995) or in the United States Pharmacopeia (USP) publication USP-NF (2004) (which is the (2004, USP-Chapter 1) r 921) and have been described in the art.
[0109] The present invention is in particular in accordance with the British Pharmacopoeia test for dispersible tablets as defined herein. This provides a dispersion that can pass through a sieve having a mesh opening of 710 μm. In order to disperse in water within 15 to 50 minutes, or 20-45 minutes, Compressed or direct compressed tablets are provided.
[0110] The tablet according to the invention and capable of dispersing quickly in water is characterized in that it has a dispersion time and dispersion quality. It has the added advantage of meeting the British Pharmacopoeia (BP) test for dispersible tablets. (i.e., pass through a 710 μm sieve). Preferably, the dispersion time of the tablets according to the invention is less than 15 minutes, more preferably less than 12 minutes. , and most preferably less than 10 minutes.
[0111] A further advantage of the tablets according to the invention is that a relatively fine dispersion is formed, which improves the dissolution of the tablets. The advantage is that the release time is short and therefore the drug can be absorbed into the bloodstream more quickly. Furthermore, the rapid dispersion times and relatively fine dispersion obtained with the tablets according to the invention It is also an advantage for tablets to be swallowed. Therefore, the tablets according to the invention can be dispersed in water and These devices according to the invention, which are intended for swallowing, can be presented both for swallowing and for direct swallowing. The tablets are preferably film coated to aid in swallowing.
[0112] In a further aspect, the present invention relates to a pharmaceutical formulation or compressed tablet as described herein. And here, i) 90 to 99.5% of the LAF237 is released between 0 and 45 minutes, and ii) 70 to 99% of metformin is released between 10 and 45 minutes. A 1000 ml sample of 0.01N HCl was used to measure the drug dissolution rate (% released). Such methods are well known and can be found in any analytical chemistry textbook, and are also used in the is the United States Pharmacopeia (USP) Publication USP-NF (2004) (which is the U.S. Food and Drug Administration (FDA) (2004-Chapter 711) It is stated as follows.
[0113] The present invention also provides i) granulating metformin and a binder; ii) drying the granules containing metformin and the binder; iii) DPP-IV inhibitors, preferably LAF237, drug substance and metformin and combination mixing with granules containing the agent; iv) Optionally, a lubricant, e.g. magnesium stearate, is added to the mixture obtained in step iii). To mix with something; A DPP-IV inhibitor, preferably LAF237 or a pharmaceutical salt thereof, and methotrexate. Also provided is a process for producing a pharmaceutical formulation comprising lumin or a pharmaceutical salt thereof.
[0114] The present invention also provides i) granulating metformin and a binder; ii) drying the granules containing metformin and the binder; iii) DPP-IV inhibitors, preferably LAF237, drug substance and metformin and combination mixing with granules containing the agent; iv) Optionally, a lubricant, e.g. magnesium stearate, is added to the mixture obtained in step iii). To mix with something; v) compressing the resulting blend to form unit dosage tablets; A DPP-IV inhibitor, preferably LAF237 or a pharmaceutical salt thereof, and methotrexate. A method for producing a pharmaceutical tablet containing Lumin or a pharmaceutical salt thereof is also provided.
[0115] The resulting blend is in the form of a tableting powder that can be compressed into tablets. The final moisture level (LOD) of the granules after drying is also important to ensure adequate pressure for metformin wet granulation. It may be necessary to obtain compression molding properties and flowability (if the LOD is reduced, compression molding Although the properties and tablet friability are poor, the granules do not cause significant picking when the LOD is increased. (which can cause the powder to break down and / or form agglomerates and begin to restrict powder flowability). The target LOD is ~2% (range 0.5 to 3.5, preferably 1.5 to 2.4%). do.
[0116] Thus, in a preferred embodiment during step ii), the granules are admixed with an LOD of 0.5-3.5%, preferably Dry to 1.5-2.4%. (LOD: Loss on Drying Method (Method defined by USP) Preferably the granulation in step i) is wet granulation or melt granulation. When metformin and a binder are granulated by melt granulation (step i), unexpectedly good The results observed are that the final formulation or tablet obtained exhibits the advantages described herein, e.g., improved It exhibits improved hardness, low friability, good compression formability, dissolution and stability.
[0117] Thus, in a preferred aspect, metformin and a binder are combined for melt granulation, The blend is then passed through an extruder. Preferably, the extruder is operated at a temperature between 140 and 220°C, or between 155 and 205°C in the mixing zone. or between 170 and 190°C. Preferably, the compression step v) is a direct compression of the blend resulting from step iii) or iv). be.
[0118] In a further embodiment, the method comprises: At the end of step i) and step ii), metformin is between 1 and 25% by weight based on the dry weight. or between 1 and 20% by weight, preferably between 1 and 20% by weight, most preferably between 3 and 5% by weight. between 4.9 and 12% by weight, or between 7.5 and 10.5% by weight, or between 7.5 and 17.5% by weight, or between 12.5 and 17.5% by weight of a pharma- ceutically acceptable This is because the composition is in the form of granules containing a binder. Step i), wherein at least one further pharma- ceutically acceptable diluent or disintegrant is added. Such excipients are added to the blended mixture. Preferably, further pharma- ceutically acceptable excipients are added to the blend. The excipient(s) do not exceed 25% of the granule weight on a dry weight basis, preferably 17.5% or less than 15%. Step iii), wherein at least one further pharma- ceutically acceptable diluent or disintegrant is added. Excipients such as drugs are added to the blended mixture. A further coating step is applied to the resulting compressed cores (tablets). Optionally, compress the cores to an LOD of <1%, preferably <0.5%, prior to tablet coating. Allow to dry.
[0119] The preferred DPP-IV inhibitor is LAF237 and the preferred diluent is microcrystalline cellulo cellulose or lactose, or preferably a combination of microcrystalline cellulose and lactose. The preferred disintegrant is sodium starch glycolate, and the preferred disintegrant is The preferred lubricant is magnesium stearate. Prior to step (1), a basic de-lumping step is performed, i.e. to remove any agglomerates / cake. It is preferred to apply a sieving step to the formulation to obtain metformin prior to step (3). A sieving step is preferably applied to the LAF237 before it is added to the granules.
[0120] In another aspect, the present invention extends to a capsule containing the pharmaceutical composition described above. The final product can be compressed into tablets, capsules, etc. using a conventional tablet press or similar machine. It is manufactured in a similar manner. 14kp and 30kp at a compression force of 15kN obtained by one of the methods described herein Between 0.5% and 0.18% for hardness and / or compressive force between 15 and 20 kN A tablet having a friability of.
[0121] Most preferably, the DPP-I for formulation, compressed tablet or processing described herein is The V inhibitor is 1-{2-[(5-cyanopyridin-2-yl)amino]ethylamino}acetamide dihydrochloride. (S)-1-[(3-hydroxy-1-adamantyl) Amino]acetyl-2-cyano-pyrrolidine, L-threo-isoleucyl thiazolidine, MK-0431, GSK23A, BMS-477118, 3-(aminomethyl)-2-iso Butyl-1-oxo-4-phenyl-1,2-dihydro-6-isoquinolinecarboxamide and 2-{[3-(aminomethyl)-2-isobutyl-4-phenyl-1-oxo-1, 2-dihydro-6-isoquinolyl]oxy}acetamide and optionally Pharmaceutical salts thereof are selected from the group consisting of:
[0122] Most preferably, the DPP-IV inhibitor is 1-[3-hydroxy-adamant-1-yl Amino)-acetyl]-pyrrolidine-2(S)-carbonitrile (LAF237 or Builder gliptin) or a pharmaceutical salt thereof. (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidone The dosage of lysine (vildagliptin) is preferably between 10 and 150 mg daily, most preferably or between 25 and 150 mg, or between 50 and 100 mg, or between 25 and 1 Preferred examples of daily oral dosages are between 25, 30, 35, 45, 50, 500 mg. The active ingredient is administered in doses of 5, 60, 70, 80, 90 or 100 mg up to three times a day. It can be preferably administered once or twice daily.
[0123] The glitazones that can be combined in the triple combination formulation of the present invention are well known in the art. This method is well known and has been described in many publications. The glitazones under development are AZ242 (AstraZeneca), phase 2; KRP-297 (Kyorin, Merc Phase 1-2: MCC-555 (licensed to Mitsubishi Chemicals, J&J) Phase 2: JTT-501 (licensed to Japan Tobacco, Pharmacia) This is the second phase of the study.
[0124] Glitazone 5-{[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]-methyl} thiazolidine-2,4-diones (pioglitazone, European Patent No. 0193256(A1)); 5-{[4-(2-(methyl-2-pyridinyl-amino)-ethoxy)phenyl]methyl}-thia Zolidine-2,4-dione (rosiglitazone, European Patent No. 0306228(A1)), 5-{ [4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-be (2-phenyl)-2-methyl-1,2-diphenyl-2,4-dione (triazolidine-2,4-dione Roglitazone, European Patent No. 0139421), (S)-((3,4-dihydro-2-(phenyl) (2H-1-benzopyran-6-yl)methyl-thiazolidine-2,4-diol (englitazone, European Patent No. 0207605(B1)), 5-(2,4-dioxothiazolidinedione Lysine-5-ylmethyl)-2-methoxy-N-(4-trifluoromethyl-benzyl) benzyl amide (KRP297, JP10087641-A), 5-[6-(2-fluoro- (2-methylphenyloxy)naphthalene-2-ylmethyl]thiazolidine-2,4-dione (MCC555, European Patent No. 0604983(B1)), 5-{[4-(3-(5-methyl-2-phenyl-4 -oxazolyl)-1-oxopropyl)-phenyl]-methyl}-thiazolidine-2,4- Dione (darglitazone, European Patent No. 0332332), 5-(2-naphthylsulfonyl) -thiazolidine-2,4-diones (AY-31637, U.S. Pat. No. 4,997,948), 5 -{[4-(1-methyl-cyclohexyl)methoxy)-phenyl]methyl}-thiazolidine- 2,4-dione (Ciglitazone, U.S. Pat. No. 4,287,200) is the generic name in each case. and specifically disclosed in the documents cited in parentheses after each substance, in each case In particular, in the case of compound claims and final products of the examples, the subject matter of the final product, pharmaceutical formulations and The disclosures and claims of these publications are incorporated herein by reference. and 5-{[4-(2-(2,3-dihydroindol-1-yl)ethoxy)phenyl]methyl The preparation of {1,3-thiazolidine-2,4-diones was reported by BB Lohray et al., J. Med. Chem. 41:161. 9-1630 (1998); Examples 2d and 3g on pages 1627 and 1628. -[3-(4-chlorophenyl)-2-propynyl]-5-phenylsulfonyl)-thiazolyl phenylethynyl as referred to herein. The compounds were prepared according to the method described in J. Wrobel et al., J. Med. Chem. 41:1084-1091 (1998). It can be carried out in accordance with the following:
[0125] In particular, MCC555 is disclosed in European Patent No. 0604983B1, page 49, lines 30 to 45. as disclosed on page 6, line 52 to page 7, line 6, or The compound can be formulated similarly to Example 27 or 28 on page 24 of State Patent No. 0207605B1. and darglitazone and 5-{4-[2-(5-methyl-2-phenyl- 4-Oxazolyl)-ethoxy)]benzyl}-thiazolidine-2,4-dione (BM-13. 1246) as disclosed in European Patent No. 0332332B1, page 8, lines 42 to 54. AY-31637 can be formulated as described in U.S. Pat. No. 4,997,948, paragraph 4, 32. As disclosed on line 51 of European Patent No. 0306228A1, and rosiglitazone as disclosed on line 51 of European Patent No. The latter is preferably administered as its maleate salt, as disclosed on pages 32 to 40 of 9. Rosiglitazone can be marketed, for example, under the trademark VANDIA™. Troglitazone can be administered in a folate-containing form, for example, under the trademarks ReZulin™, PRELAY™, It is administered in the form as it is marketed under the trademark ROMOZIN (UK) or NOSCAL (Japan). Pioglitazone can be used as disclosed in Example 2 of European Patent No. 0193256A1. It can be administered preferably in the form of the monohydrochloride, as needed for one patient's needs. Correspondingly, pioglitazone is administered in the form as it is marketed under the trademark ACTOS™. Ciglitazone can be used, for example, as disclosed in Example 13 of U.S. Pat. No. 4,287,200. The composition can be formulated to provide a
[0126] For example, the daily dose of glitazones for an adult diabetic patient (body weight: 50 kg) is The dosage is usually from 0.01 to 1000 mg, preferably from 0.1 to 500 mg. can be administered once or several times a day. In particular, pioglitazone hydrochloride is effective in reducing insulin sensitivity. When used as an improvement drug, the daily dose of pioglitazone hydrochloride is usually 7.5 to Troglitazone is used to improve insulin sensitivity. When used as a medicine, the daily dose of troglitazone is usually between 100 and 1000 mg. , preferably 200 to 600 mg. When used as an insulin sensitizer, the daily dose of rosiglitazone is usually 1 to 12 mg, preferably 2 to 12 mg.
[0127] The glitazone is preferably pioglitazone, pioglitazone hydrochloride, troglitazone or Rosiglitazone (or its maleate salt), particularly preferred is pioglitazone hydrochloride. ACTOS® (pioglitazone) is used as monotherapy or in combination with sulfonylureas, metformin, The dose should not exceed 45 mg once daily in combination with methotrexate or insulin. ACTOS in combination with Ming can be initiated at 15 mg or 30 mg once daily. Current metformin doses can be continued at the initiation of ACTOS treatment. It is unlikely that hypoglycemia will require metformin dose adjustment during treatment. S is available in 15 mg, 30 mg and 45 mg tablets.
[0128] AVANDIA® (rosiglitazone) is administered as a once-daily dose at a starting dose of 4 mg. The dose can be taken in one dose or divided and administered in the morning and evening. Week 8 to 12 of treatment Subsequently, in patients with an inadequate response as determined by a decline in FPG, The dose can be increased to 8 mg daily or combined with metformin. The dose of DIA should not exceed 8 mg per day as a single dose or divided into two doses per day. AVANDIA is available in 2 mg, 4 mg and 8 mg tablets.
[0129] Metformin dosing for diabetes is individualized based on efficacy and tolerability. should not exceed the maximum recommended daily dose of metformin, which is 2000 mg. Metformin is widely prescribed to lower blood glucose in patients with NIDDM and It is commercially available in strengths of 500, 750, 850 and 1000 mg. Because it is a short-acting drug, metformin can be administered twice or three times a day (500 mg / day). - 2-3 850 mg tablets / day or 1000 mg twice daily with meals) is required. The dosage used in the present invention is between 250 and 2000 mg, preferably between 250 and 1000 mg. Metformin or its pharmaceutical salts are between 250 mg, 500 mg, 85,000 mg. The pharmaceutical composition according to the invention described herein, including tablets or Or capsules.
[0130] Thus, in a further aspect, the present invention relates to a composition comprising an active ingredient comprising: i) Metformin 50 to 2000 mg, preferably Metformin 250 to 1000 mg g; ii) a DPP-4 inhibitor, preferably vildagliptin 25 to 100 mg; The present invention relates to a tablet or formulation comprising:
[0131] The present invention also provides The active ingredient is; i) Metformin 50 to 2000 mg, preferably Metformin 250 to 1000 mg g; ii) a DPP-4 inhibitor, preferably vildagliptin 25 to 100 mg, preferably vildagliptin 25 to 50 mg; The present invention also relates to a pharmaceutical unit dosage form, preferably a tablet or capsule, comprising the formulation of the present invention. do.
[0132] The present invention also provides The active ingredients are: i) Vildagliptin 25 mg and Metformin 250 mg or its respective Medicinal salts; ii) vildagliptin 25 mg and metformin 500 mg or each of its equivalents Medicinal salts; iii) vildagliptin 25 mg and metformin 850 mg or each in its respective case Pharmaceutical salts of; iv) vildagliptin 25 mg and metformin 1000 mg or each in its respective case Pharmaceutical salts of; v) Vildagliptin 50 mg and Metformin 500 mg or its equivalent in each case Medicinal salts; vi) vildagliptin 50 mg and metformin 850 mg or in each case Medicinal salts; vii) Vildagliptin 50 mg and Metformin 1000 mg or each in each case its pharmaceutical salts; The present invention also relates to a pharmaceutical unit dosage form, preferably a tablet or capsule, comprising the formulation of the present invention. do.
[0133] The present invention also provides a) The active ingredient is: i) Vildagliptin 25 mg and Metformin 250 mg or its respective Medicinal salts; ii) vildagliptin 25 mg and metformin 500 mg or each of its equivalents Medicinal salts; iii) vildagliptin 25 mg and metformin 850 mg or each in its respective case Pharmaceutical salts of; iv) vildagliptin 25 mg and metformin 1000 mg or each in its respective case Pharmaceutical salts of; v) Vildagliptin 50 mg and Metformin 500 mg or its equivalent in each case Medicinal salts; vi) vildagliptin 50 mg and metformin 850 mg or in each case Medicinal salts; vii) Vildagliptin 50 mg and Metformin 1000 mg or each in each case its pharmaceutical salts; Consists of; and b) Metformin in a binder (1 to 25% of the weight of the granules on a dry weight basis) of 1 to 25% ), in the form of granules containing between 1 and 20% binder, or between 7.5 and 17.5% binder. can be; c) the composition or tablet is between 50 and 98% by weight, based on dry weight, between 6% by weight, between 60% by weight and 98% by weight, between 60% by weight and 96% by weight, or between 70 and 98% by weight, between 70 and 96% by weight, between 80 and 98% by weight, contains between 80 and 96% by weight of active ingredient; d) The composition optionally contains between 0.1% and 2% of at least one oleic acid salt, such as magnesium stearate. and one further excipient; It also relates to a formulation or tablet according to the invention.
[0134] The present invention also provides pharmaceutical unit dosage forms, preferably tablets or capsules, containing the formulations of the present invention. Also relates to the compound, wherein the active ingredient is i) between 50 and 2000 mg of metformin, preferably between 250 and 1000 mg metformin; ii) between 25 and 100 mg of a DPP-4 inhibitor, preferably vildagliptin, or between 25 and 50 mg of vildagliptin; and iii) between 2 and 50 mg of a glitazone, preferably between 2 and 8 mg of rosiglitazone or between 15 and 45 mg of pioglitazone; It consists of:
[0135] Thus in a further aspect, the present invention comprises - Tablet hardness is between 60 and 340 N; - Tablet friability is less than 0.8%; and - Tablet thickness is between 4.5 and 8.3 mm; The present invention relates to a tablet.
[0136] Thus, in a further aspect, the present invention provides a method for producing a method of making a - Tablet hardness is between 60 and 340 N; - Tablet friability less than 0.8%; - the tablet thickness is comprised between 4.5 and 8.3 mm; and By using the paddle method, - At least 70% of vildagliptin is dissolved within 30 minutes; - At least 80% of the metformin HCl dissolves within 45 minutes; The present invention relates to a tablet.
[0137] In a further aspect, the present invention relates to a tablet according to the invention, wherein metformin is in the form of its HCl salt. Or relating to formulations. Between 50 and 98% by weight, between 50 and 96% by weight, between 60 and 70% by weight, based on dry weight between 60% and 96% by weight, or between 70 and 98% by weight. between 70% and 96% by weight, between 80 and 98% by weight, or between 80 and 96% by weight. % active ingredient, where the active ingredients are vildagliptin and metformin or Any of the compositions described herein, in each case consisting of a pharma- ceutically acceptable salt thereof. Or tablets.
[0138] In a further aspect, the present invention relates to a method for treating non-insulin dependent diabetes mellitus, arthritis, obesity, allografts, cancer, and the like. Lucitonin - osteoporosis, heart failure, glucose metabolism disorder, IGT (impaired glucose tolerance), Alzheimer's Treatment of conditions such as neurodegenerative diseases such as Merck's disease and Parkinson's disease; For the modulation of symptoms related to hyperlipidemia, or for the regulation of VLDL, LDL and Lp(a) levels To reduce heart rate, cardiovascular or renal diseases, such as diabetic cardiomyopathy, left or right ventricular Ventricular hypertrophy, hypertrophic medial thickening of the arteries and / or great vessels, Mesenteric vascular hypertrophy, mesenteric hypertrophy, neurodegenerative and congestive disorders, sedative or anxiolytic effects To produce beneficial effects and attenuate the hormonal response to catabolic changes and stress following surgery , to reduce mortality and morbidity after myocardial infarction, The present invention relates to a method for treating diseases associated with the above effects that can be mediated by .DELTA.-2 levels, as described herein. This document relates to the use of formulations, capsules, tablets, compressed tablets, and direct compressed tablets.
[0139] In each case, especially in compound claims, the final product of the embodiment, the object of the final product substances, analytical and measurement methods (e.g. USP documents), methods for obtaining accurate particle size, pharmaceutical formulations, The excipients and claims are incorporated herein by reference in their entirety to the publications or patent applications referred to herein. and is hereby incorporated by reference. The present invention is further illustrated by the following examples: EXAMPLES
[0140] Example 1: Manufacturing method Since metformin drug substance solidifies during storage, a vibrating mill (Frew A decompaction step using itt is then required. Metformin is then added. Mix in a high shear mixer for 1-2 minutes with HPC-EXF (EXF: Manufacturer's (Aqua) for viscosity and particle size). lon) grade designation, x = xtrafine, HF = meaningless, other HPC grades HF, GF, Mix 9 (w / w)% HPC solution with sufficient granules (similar viscosity designation for LF and EF). Pump into a high shear granulator at a constant rate (4 min) until granules form (~7% total amount of water). The granules are then dried in a fluid bed dryer until the final LOD (loss on drying) is ~2% (range 1.5 to 2.4%). The dried granules are then passed through a Fitzmill (fitted with a 0.078" or 2 mm sieve) or a Frewijn tt oscillator (equipped with a 1.68 mm sieve). Pass it through a sieve and blend it with the crushed metformin granules in a bin blender for 300 revolutions. Magnesium stearate was also passed through a 1 mm handheld sieve and mixed with the Met / LAF mixture. The mixture is then compressed in a rotary tablet press. The compressed cores are then placed in a tablet press. Dry to LOD < 0.5% before coating. Coating weight approximately 5mg / cm 2 is applied during the coating process.
[0141] Metformin:LAF237 nuclear transfer in ratios of 5:1, 10:1, 20:1, and 40:1 The process parameters used to manufacture batches of the formulations described herein, including Tar [Table 1]
[0142] Description of the manufacturing equipment used for the development of the formulations described herein [Table 2]
[0143] Batch size to be tested Batch sizes for test batches were typically <1.0 kg. , wet mixed in a 25L Collette Gral mixer with batch sizes ranging from 3.0 to 6.0 kg. The granulation was completed. Notes on the scalability and robustness of the final process All processes incorporating the manufacture of metformin wet granulation and drying processes, as well as mixing; Compression and coating are standard methods and use standard equipment. FBD (Fluid Bed Drying) End point LOD (1.5-2.4%) of the drying process. Since the moisture level of the dry granules has a significant effect on the tableting properties, all granules were dried in KG 5 mixer and then heated in an oven to approximately 2% LOD (preferred range is 1.5 Dry to -2.4%).
[0144] Manufacturing method: Alternative method Step 1: Metformin and HPC are sieved through a 1700 μm sieve. The mixture is placed in a diffusion blender and premixed for 200 revolutions at 20 rpm. Step 2: The blend is passed through a twin screw extruder set at 180°C (in the mixing zone) - melt granulation. Step 3: Screen the granules through a 500 μm sieve using a frewitt (grinding step). Step 4: Sieve LAF237 through a 500 μm sieve and mix with the granules from step 3 and 20 rp Mix at 300 rpm. Step 5: Sieve magnesium stearate through a 1000 μm sieve and add 20 rp Mix at 60 rpm for 30 min. Step 6: Compression of the resulting composition. Step 7: Film coating.
[0145] Example 1B: Preparation of Metformin using Melt Granulation: [Table 3] The internal phase components, namely metformin hydrochloride and methacrylate, were obtained from Hercules Chemical Co. (Wilmington, Dela and hydroxypropyl cellulose available as KLUCEL EXF from Eppendorf Chemicals, Inc. The mixture is then mixed in a bin blender for approximately 200 revolutions. The mixture is then fed into the feed section of a twin screw extruder or A suitable twin screw extruder is available from Thermo Electron Corp. (Waltham, Massachusetts). The PRISM 16mm is a twin screw pharmaceutical extruder available from USETTS.
[0146] At the end of the twin-screw extruder is a die with an inner diameter of approximately 3 mm. The extruder is made up of five individual barrel zones or sections, each individually tuned to different parameters. Starting from the hopper to the mold, the zones are each heated to the following temperatures: The temperatures of the heating zones are: 40°C, 110°C, 130°C, 170°C and 185°C. The melting temperature of metformin hydrochloride, which is 232°C, is not exceeded. The screw speed is 150 rpm. The feed rate is set at about 30 to 400 rpm, but can be as low as 400 rpm, and the volume feed rate is about 30 to 400 rpm. The output can be adjusted from 4g / min to 80g / min. Cut.
[0147] The extrudate or granules from the extruder are then allowed to stand for approximately 15 to 20 minutes to form a chamber. The cooled granules are then sieved through a 500 μm sieve (i.e., a 1 mm sieve). do.
[0148] For the external phase, magnesium stearate is sieved through a 1000 μm sieve, and Vildagliptin bulk material is first passed through a 500 μm sieve. Vildagliptin is then mixed with the appropriate The resulting granules are mixed with a stationary blender for approximately 150 or 300 revolutions. The magnesium phosphate is mixed with the resulting mixture for 50 or 70 revolutions. The final blend was compressed in a conventional rotary tablet press (Manesty Beta Press) at a pressure range between 6kN and 25kN. The resulting tablets are monolithic and have a compression force of 5 kP to 3 kP. Tablets having a hardness ranging from 15 kP to 35 kP are 500 After 10 drops, the acceptable friability of the tablets was less than 1.0 wt / wt%. Disintegration time is less than 20 minutes using disks at 37° C. in 0.1 N HCl.
[0149] Example 2 A. Summary of Extended Conformance Testing Excipient compatibility studies of the formulations described herein with standard excipients were performed at 50°C / 75% (open) for 4 weeks. Based on the compatibility results, the data indicate that the formulations described herein and that the tablets did not significantly degrade metformin or LAF237. .
[0150] B. Stability Protocol Stability studies on induction sealed HDPE bottles At 25°C / 60%RH, 30 / 65%RH and 40°C / 75%RH with medium desiccant, As well as without a desiccant, the experiment was carried out at 40°C / 75%RH in the open (open). Stability at various times The properties of the formulations and tablets described herein have shown good results. RH = relative humidity
[0151] (a) Table i) Storage conditions for stability of test formulations [Table 4]
[0152] (b) Table ii) Stability storage conditions for melt granulation and low moisture systems [Table 5] Stability Results: Good stability was obtained with the formulations and tablets described herein.
[0153] Stability of low moisture formulations, Met:LAF 40:1 ratio (Metformin Direct Compression) (marketed as a "new grade" for direct compression into tablets) (Pre-granulated material) + LAF237 (solvent granulation) are stored in a sealed container at 40℃ / 75%RH for 6 weeks. Under the storage conditions, the total degradation of LAF237 was 2.9%. (Metformin water granulated with 6.6% HPC) + LAF237 (solvent granulated) (claimed The formulation) resulted in 0.9% total decomposition of LAF237 when stored in a sealed container for 6 weeks at 40℃ / 75% RH. Simultaneous granulation of (metformin + LAF237) with 6.6% HPC at 40℃ / 75%RH +6 weeks of closed storage resulted in 6.6% total degradation of LAF237.
[0154] In addition, applicants have tested a number of other formulations and have demonstrated that DPP-IV inhibitors and methotrexate are effective in treating Formulations containing luminin and having a high drug load (e.g., unit dose tablets) are particularly The presence of an agent, preferably HPC, provides better stability results. We found that.
[0155] C. Test conditions for dissolution rate The methods chosen were those at different pH (0.01N HCl, pH 4.5 and pH 6. 8 Buffer) Previous studies showing similar release profiles of metformin and LAF237 Results from method development studies and from paddle or basket (50 and 100 rpm) Based on the results. USP Apparatus: I (Basket) Rotation speed: 100 rpm Dissolution solvent: 0.01N HCl, degassed Capacity: 900ml Dissolution was performed on the first sample only (n=3). Dissolution of the stability samples using the agent shows good results. The dissolution rate requirements are met. There are.
[0156] 3.Composition: Exemplary compositions for all dosage strengths are listed in Tables 3-1 through 3-6. [Table 6] a Removed during processing. * Calculated based on 9 (w / w)% metformin HCl and total HPC.
[0157] [Table 7] a Removed during processing. * Calculated based on 9 (w / w)% metformin HCl and total HPC.
[0158] [Table 8] a Removed during processing. * Calculated based on 9 (w / w)% metformin HCl and total HPC.
[0159] [Table 9] a Removed during processing. * Calculated based on 9 (w / w)% metformin HCl and total HPC.
[0160] [Table 10] a Removed during processing. * Calculated based on 9 (w / w)% metformin HCl and total HPC.
[0161] [Table 11] a Removed during processing. * Calculated based on 9 (w / w)% metformin HCl and total HPC.
[0162] Example 4 Tablets prepared according to the above descriptions and examples can be tested as follows: Cut. Tablet Evaluation Method 1. Average tablet weight. 24 tablets were weighed on an analytical balance and the average tablet weight was calculated. do. 2. Tablet breaking strength (kilobond - kp). Tablets were tested separately using a Schleuniger hardness tester. The breaking strength is then calculated. 3. Friability (loss %). Ten accurately weighed tablets were fried for 10 minutes using a Roche friability tester. The tablets are then subjected to a friability test. The tablets are dedusted, reweighed, and the weight loss due to friability is calculated based on the initial weight. Calculate as a percentage of the amount. 4. Dispersion time DT (defined in the British Pharmacopoeia 1988, Volume II, page 895-BP1988) Test for dispersible tablets (dispersible tablets) as defined above. The tablets are tested according to the method described above (none), which utilizes water at a temperature of 19°C-21°C. 5. Dispersion quality. According to the BP uniformity of dispersion test on dispersible tablets (BP 1988 Volume II page 895), place two tablets in 100 ml of water at 19°C-21°C and disperse. do.
[0163] Granule evaluation method 1. Loss on Drying (LOD). Measured using a Computrac moisture analyzer set at 90°C according to the manufacturer's procedure. Determine the residual moisture content of the granules (LOD) for 3-4 g samples by operating according to can be done. 2. Weight Median Diameter (WMD). A 10 g sample of granules was sieved through an Allen Bradley sonic sieve according to the manufacturer's instructions. Sieve for 2 minutes using the appropriate pulse and sieve size according to: 300 μm, 250 μm, 20 Sieves of 0 μm, 150 μm, 100 μm, 53 μm and 40 μm are used. The WMD is calculated from the cumulative percentage undersize distribution using the .
[0164] Example 5: Improved manufacturing robustness Precompression moldability evaluation is performed on a Carver press using various formulations. The data show that our claimed compositions were compressed at increasing pressure levels. In particular, the tablet strength of the granules described herein is well suited for use in tablet preparations. The formulations shown in this study show good tablet strength and compression moldability. The formulations and selected ranges claimed by them exhibit a substantial and useful increase in tablet strength.
[0165] The Korsch machine was instrumented with force and displacement sensors on both the upper and lower punches. Compression moldability studies using a glue station press (D. Becker, personal communication) The following will be implemented. These data show that if sufficient bulking agent with good compression moldability is not used for dilution, L There is a clear indication that AF237 tablets are very likely to have poor tablet hardness / crushing strength. However, the formulations and selected ranges that we claim are specifically LAF237 :metformin ratio of 1:5. The results obtained suggest that metformin granules may be, for example, between 1 and 20%, preferably between 3 and 40%. Convenient tablet formulations containing between 13% and between 3 and 17.5% HPC or other binders. It is shown that the hardness of the agent can be obtained.
[0166] Example 6: Friability Evaluations are performed using the Manesty Betapress at six different settings: Strain rate setting 66 -90 rpm (63000-86000 TPH) and force 7.5-15 kN. The test was conducted for 25 The diameter of the test tablets was 9 mm for the 30 mg tablets and 10 mm for the 310 mg tablets ( Use flat bevel edge (FFBE) tools (other diameters may be used depending on weight). The measurements included the degree of compression, the strain rate profile and the weight variation. Using the friability results from the design and study, variables that influence the hardness results (formulation We determine the particle size distribution in the tablet, tablet weight, tablet thickness and weight, water content in the tablet, etc. The claimed formulations and selected ranges are particularly suited to provide the required friability. There are.
[0167] Example - Metformin:LAF237 ratio 20:1 tablets: Results show LAF237+( Tablets containing metformin granules without the combination drug had a friability of approximately 0.8%, while LAF 237+ (metformin granules containing 12% HPC) had a friability of less than 0.2% (compression force of 15 kN ).
[0168] Example 7: Mechanical stress (particle size distribution) The material in the desired particle size range can be mixed with any form of vildagliptin, e.g., amorphous vildagliptin. This stress can be generated by impact, shear or compression. Most commercially available grinding equipment does not allow these A combination of principles is used. For vildagliptin, it is preferable to use a mechanical impact mill or The most preferred mechanical impact mills are those with different types of beaters, sieves, It can be installed with a liner or with a pin plate. Our method includes It is preferable to use an impact mill with a Tobeater and a slit screen 5×2.5 cm. Impact velocities (as peripheral velocities) were varied between 20 and 100 m / s for any batch. The fluctuations should be adapted. In our case the beater peripheral speed is about 40-50m / s. is used.
Claims
1. The active ingredients are vildagliptin and metformin or, in each case, their pharma- ceutical acceptable salts. Between 50 and 98% by weight, based on dry weight, %, 70 to 98% or 80 to 98% by weight of the active ingredient.
2. The active ingredients are vildagliptin and metformin or, in each case, their pharma- ceutical acceptable salts. Between 50 and 98% by weight, based on dry weight, %., between 70 and 98% by weight, or between 80 and 98% by weight of the active ingredient. or directly compressed tablets.
3. The active ingredients are vildagliptin and metformin or, in each case, their pharma- ceutical acceptable salts. Between 50 and 96% by weight, based on dry weight, 5. The composition of claim 1, comprising between 70 and 96% by weight of the active ingredient.
3. A composition or tablet according to any one of claims 1 to 2.
4. 4. The composition according to claim 1, further comprising at least one pharma- ceutically acceptable excipient. Composition or tablet.
5. A composition or tablet according to any one of claims 1 to 4, wherein metformin is in the form of granules. 。
6. Metformin is in the form of granules, wherein the granules contain at least one pharma- ceutically acceptable A composition or tablet according to claim 5 comprising an excipient.
7. 7. Any of claims 5 to 6, wherein the metformin is in the form of granules, and wherein the granules contain a binder. A composition or tablet as described above.
8. 8. Any of claims 5 to 7, wherein the metformin is in the form of granules containing between 1 and 25% binder. A composition or tablet as described above.
9. i) between 1 and 25% by weight, between 1 and 20% by weight or between 1 and Between 12% by weight of a pharma- ceutically acceptable binder; ii) between 2.9 and 11% by weight or between 6.5 and 9.5% by weight on a dry weight basis a pharma- ceutically acceptable binding agent; or iii) between 7.5 and 17.5% by weight or between 12.5 and 17.5% by weight on a dry weight basis % of a pharma- ceutically acceptable binder; 9. A composition or tablet according to any one of claims 1 to 8 comprising:
10. Metformin granules and vildagliptin and optionally at least one pharma- ceutically acceptable 10. A tablet according to any one of claims 1 to 9, obtained by direct compression with excipients which are
11. As an active ingredient, i) between 1.5 and 35% DPP-IV inhibitor or a pharma- ceutically acceptable salt thereof; ii) between 65 and 98.5% metformin or a pharma- ceutically acceptable salt thereof; wherein the metformin is in the form of granules containing between 1 and 25% of a binder. Composition or tablet.
12. As an active ingredient, i) between 1.5 and 20% vildagliptin or a pharma- ceutically acceptable salt thereof; ii) between 80 and 98.5% metformin or a pharma- ceutically acceptable salt thereof; wherein the metformin is in the form of granules containing between 1 and 25% binder.
12. A composition or tablet according to any one of 1 to 11.
13. The granules, i) between 1 and 20% by weight, or between 3 and 13% by weight, of a pharmaceutical Acceptable binders; ii) between 4.9 and 12% by weight or between 7.5 and 10.5% by weight on a dry weight basis or a pharma- ceutically acceptable binding agent of iii) between 7.5 and 17.5% by weight or between 12.5 and 17.5% by weight on a dry weight basis % of a pharma- ceutically acceptable binder; 13. A composition or tablet according to any one of claims 7, 8, 11 or 12, comprising:
14. The binder is starch; cellulose and its derivatives; sucrose; dextrose; cocoa.
14. The method according to claim 7, wherein the active ingredient is selected from the group consisting of glycerin syrup; polysaccharides; and gelatin. The composition or tablet described above.
15. Binders are microcrystalline cellulose, hydroxypropyl cellulose, and hydroxyethyl cellulose. cellulose and hydroxypropylmethylcellulose; or A composition or tablet according to any one of claims 7 to 14 which is a derivative thereof.
16. At least one conventional pharma- ceutically acceptable excipient may be added to the composition.
16. A composition or tablet according to any one of claims 1 to 15.
17. Pharmaceutically acceptable excipients include binders, diluents, disintegrants, lubricants, solid fillers, and flow enhancers.
17. A composition or tablet according to any one of claims 4 to 16, selected from an agent and a carrier.
18. The composition is 25% or 20% by weight based on the dry weight, preferably 17.5, 15 % by weight or 11% by weight or less of a pharma- ceutically acceptable binder.
18. A composition or tablet according to any one of claims 1 to 17.
19. i) between 1 and 12% by weight or between 2.9 and 11% by weight of a pharmaceutical agent on a dry weight basis and optionally between 0.1 and 10% by weight based on the dry weight of the additional pharma- ceutically acceptable excipients; or ii) between 7.5 and 17.5% by weight or between 12.5 and 17.5% by weight on a dry weight basis % of a pharma- ceutically acceptable binder and optionally 0.1 to 10% based on dry weight. % by weight of additional pharma- ceutically acceptable excipients; 19. A composition or tablet according to any one of claims 1 to 18 comprising:
20. 20. The composition according to any one of claims 4 to 19, wherein the further pharma- ceutical acceptable excipient is a lubricant. Composition or tablets.
21. Between 0.1% and 5%, between 0.1% and 2%, or between 0.5% and 5% by weight of the composition.
20. Any of claims 4 to 19, comprising between 1.5% by weight and 1.5% by weight of a pharma- ceutically acceptable lubricant. The composition or tablet described above.
22. 22. The composition according to claim 20 or 21, wherein the lubricant is magnesium stearate. tablet.
23. 5. The metformin granules according to claim 4, wherein the metformin granules are prepared by wet granulation or melt granulation together with a binder.
23. A composition or tablet according to any one of claims 22 to 22.
24. Metformin granules are mixed with water or ethanol, isopropanol, ethyl acetate, glycosylation The composition is prepared by wet granulation using a solvent selected from ethanol or propylene glycol.
24. A composition or tablet according to any one of claims 5 to 23.
25. DPP-IV inhibitors are 1-{2-[(5-cyanopyridin-2-yl)amino]ethyl dihydrochloride {amino}acetyl-2(S)-cyano-pyrrolidine, vildagliptin, L-threo- Solysylthiazolidine, MK-0431, GSK23A, BMS-477118, 3- (Aminomethyl)-2-isobutyl-1-oxo-4-phenyl-1,2-dihydro-6- Isoquinolinecarboxamide and 2-{[3-(aminomethyl)-2-isobutyl-4- phenyl-1-oxo-1,2-dihydro-6-isoquinolyl]oxy}acetamide and and optionally in each case a pharmaceutical salt thereof according to claim 11 or 13 to 24. A composition or tablet as described above.
26. The DPP-IV inhibitor is vildagliptin or a pharmaceutical salt thereof, and 25. A composition or tablet according to any one of claims 1 to 24, which contains between 35% and 40% of the active ingredient. 。
27. 27. The composition according to any one of claims 1 to 26, wherein the vildagliptin is in the form of particles. is a tablet.
28. the vildagliptin is in particulate form; i) where at least 40%, preferably 60%, most preferably 80% or 90% of vildagliptin having a particle size distribution of less than 250 μm; ii) wherein at least 40%, preferably 60%, most preferably 80% or 90% % of the vildagliptin has a particle size distribution between 10 and 250 μm; or iii) wherein at least 25% or at least 35% of the particle size distribution is between 50 and 150 μm; 28. A composition or tablet according to any one of claims 1 to 27.
29. The pharmaceutical composition may be in a capsule or in the form of a tablet, compressed tablet or direct compressed tablet.
29. The pharmaceutical composition according to any one of claims 1 to 28.
30. Metformin granules and vildagliptin and optionally at least one pharma- ceutically acceptable 30. A tablet according to any one of claims 12 to 29, obtained by direct compression with excipients which are
31. Further film coating, such as by film coating of Opadry premix 21. The tablet according to claim 2 or 10 to 20.
32. 32. The pharmaceutical preparation according to any one of claims 1, 3 to 31, which corresponds to one layer of a bilayer or trilayer tablet. A pharmaceutical composition comprising:
33. i) between 25 mg and 100 mg of vildagliptin or a pharmaceutical salt thereof; or ii) 25 mg, 50 mg, or 100 mg of vildagliptin or a pharmaceutical salt thereof ; 33. The composition or tablet of any one of claims 1 to 32, comprising:
34. i) metformin between 50 and 2000 mg or between 250 and 1000 mg or pharmaceutical salts thereof; or ii) 250 mg, 500 mg, 850 mg, or 1000 mg of metformin or a pharmaceutical salt thereof; 34. The composition or tablet of any one of claims 1 to 33, comprising:
35. i) vildagliptin 25 mg and metformin 250 mg or in each case its Pharmaceutical salts; ii) vildagliptin 25 mg and metformin 500 mg or in each case its equivalent Pharmaceutical salts; iii) vildagliptin 25 mg and metformin 850 mg or in each case Pharmaceutical salts of iv) vildagliptin 25 mg and metformin 1000 mg or in each case Pharmaceutical salts of v) Vildagliptin 50 mg and Metformin 500 mg or its equivalent in each case. Medicinal salts; vi) vildagliptin 50 mg and metformin 850 mg or in each case its equivalent Pharmaceutical salts; vii) vildagliptin 50 mg and metformin 1000 mg or in each case Pharmaceutical salts thereof; 35. The composition or tablet of any one of claims 1 to 34, comprising:
36. A sulfonylurea or a glitazone such as pioglitazone or rosiglitazone.
36. A composition or tablet according to any one of claims 1 to 35, comprising a further active ingredient comprising
37. i) granulating metformin and a binder; ii) drying the granules containing metformin and the binder; iii) Mixing the DPP-IV inhibitor, drug substance, with granules containing metformin and a binder To do so; iv) Optionally, a lubricant, e.g. magnesium stearate, is added to the mixture obtained in step iii). To mix with something; and metformin or any pharmaceutical salt thereof. A method for producing a pharmaceutical composition.
38. i) granulating metformin and a binder; ii) drying the granules containing metformin and the binder; iii) Mixing the DPP-IV inhibitor, drug substance, with granules containing metformin and a binder To do so; iv) Optionally, a lubricant, e.g. magnesium stearate, is added to the mixture obtained in step iii). To mix with something; v) compressing the resulting blend to form unit dosage tablets; and metformin or any pharmaceutical salt thereof. A method for producing a pharmaceutical tablet.
39. During step ii) the granules are dried to an LOD of 0.5-3.5%, preferably 1.5-2.4%.
39. The method of claim 37 or 38, wherein
40. At the end of step ii), metformin or a pharmaceutical salt thereof is added in an amount of 1 to 2 g based on dry weight. between 5% by weight, or between 3 and 13% by weight, or between 4.9 and 12% by weight, or Between 7.5 and 10.5% by weight, or between 7.5 and 17.5% by weight, or between 12.5 and 37 to 39, which is in the form of granules containing between 17.5% by weight of a pharma- ceutically acceptable binder.
38. The method according to any one of claims 38 to 38.
41. At least one further drug is added to the mixture that is mixed during step i) or during step iii).
41. The method of any of claims 37 to 40, wherein a physiologically acceptable excipient is added.
42. 42. The method according to claim 41, wherein the further pharma- ceutical acceptable excipient is a diluent or a disintegrant. Law.
43. 38 to 4, wherein a further coating step is applied to the tablets obtained from step v).
2. The method according to any one of claims 1 to 11.
44. 44. The method according to any one of claims 37 to 43, wherein the granulation in step i) is melt granulation or wet granulation. How to.
45. Metformin and a binder are blended and the blend is passed through an extruder for melt granulation.
45. The method of any of claims 37 to 44, comprising granulation step i).
46. The extruder is heated to between 140 and 220°C in the mixing zone, or between 155 and 205°C, or 46. The method of claim 45, wherein the temperature is set between 170 and 190°C.
47. Binders are microcrystalline cellulose, hydroxypropyl cellulose, and hydroxyethyl cellulose. cellulose and hydroxypropylmethylcellulose; or 47. A method according to any one of claims 37 to 46, which is a derivative thereof.
48. 48. Any of claims 37 to 47, wherein the DPP4 inhibitor is vildagliptin or a pharmaceutical salt thereof. Any of the methods described above.
49. The metformin is in the form of metformin HCl and the DPP4 inhibitor is vildagliflozin.
37. The pharmaceutical composition or pharmaceutical salt thereof according to any one of claims 1 to 36, A tablet or the method according to any one of claims 36 to 46.
50. Tablet hardness is comprised between 60 and 340 N; Tablet friability is less than 0.8%; and The thickness of the tablet is comprised between 4.5 and 8.3 mm; 50. A tablet according to any one of claims 1 to 49.
51. Tablet hardness is comprised between 60 and 340 N; Tablet friability is less than 0.8%; and The thickness of the tablet is comprised between 4.5 and 8.3 mm; By using the paddle method, at least 70% of vildagliptin was dissolved within 30 minutes. Can be; At least 80% of metformin HCl dissolved within 45 minutes using the paddle method do; 51. The tablet of claim 50.
